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A B S T R A C T
Background
Peptic ulcer disease is the cause of dyspepsia in about 10% of people. Ninety-five percent of duodenal and 70% of gastric ulcers
are associated with Helicobacter pylori. Eradication of H. pylori reduces the relapse rate of ulcers but the magnitude of this effect
is uncertain. This is an update of Ford AC, Delaney B, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in
Helicobacter pylori-positive patients. Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No.: CD003840. DOI: 10.1002/
14651858.CD003840.pub4.
Objectives
To assess the proportion of peptic ulcers healed and the proportion of participants who remained free from relapse with eradication
therapy against placebo or other pharmacological therapies in H. pylori-positive people.
To assess the proportion of participants that achieved complete relief of symptoms and improvement in quality of life scores.
To compare the incidence of adverse effects/drop-outs (total number for each drug) associated with the different treatments.
To assess the proportion of participants in whom successful eradication was achieved.
Search methods
In this update, we identified trials by searching the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE
(1950 to March 2016) and Ovid EMBASE (1980 to March 2016). To identify further relevant trials, we handsearched reference
lists from trials selected by electronic searching, and published abstracts from conference proceedings from the United European
Gastroenterology Week (published in Gut) and Digestive Disease Week (published in Gastroenterology). The search was last updated
in March 2016. We contacted members of Cochrane Upper GI and Pancreatic Diseases, and experts in the field and asked them to
provide details of outstanding clinical trials and any relevant unpublished materials.
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Selection criteria
We analysed randomised controlled trials of short- and long-term treatment of peptic ulcer disease in H. pylori-positive adults. Par-
ticipants received at least one week of H. pylori eradication compared with ulcer healing drug, placebo or no treatment. Trials were
included if they reported assessment from two weeks onwards.
Data collection and analysis
We collected data on ulcer healing, recurrence, relief of symptoms and adverse effects. We calculated the risk ratio (RR) with 95%
confidence intervals (CI) using both fixed-effect and random-effects models with Review Manager software (RevMan 5.3) based on
intention-to-treat analysis as far as possible.
Main results
A total of 55 trials were included for one or more outcomes for this review.
In duodenal ulcer healing, eradication therapy was superior to ulcer healing drug (UHD) (34 trials, 3910 participants, RR of ulcer
persisting = 0.66, 95% confidence interval (CI) 0.58 to 0.76; 381/2286 (adjusted proportion: 12.4%) in eradication therapy plus
UHD versus 304/1624 (18.7%) in UHD; low quality evidence) and no treatment (two trials, 207 participants, RR 0.37, 95% CI 0.26
to 0.53; 30/125 (adjusted proportion: 21.7%) in eradication therapy versus 48/82 (58.5%) in no treatment; low quality evidence).
In gastric ulcer healing, the differences were imprecise between eradication therapy and UHD (15 trials, 1974 participants, RR 1.23,
95% CI 0.90 to 1.68; 220/1192 (adjusted proportion: 16.0%) in eradication therapy plus UHD versus 102/782 (13.0%) in UHD;
very low quality evidence). In preventing duodenal ulcer recurrence the differences were imprecise between maintenance therapy with
H.pylori eradication therapy and maintenance therapy with UHD (four trials, 319 participants, RR of ulcer recurring 0.73; 95% CI
0.42 to 1.25; 19/159 (adjusted proportion: 11.9%) in eradication therapy versus 26/160 (16.3%) in UHD; very low quality evidence),
but eradication therapy was superior to no treatment (27 trials 2509 participants, RR 0.20, 95% CI 0.15 to 0.26; 215/1501 (adjusted
proportion: 12.9%) in eradication therapy versus 649/1008 (64.4%) in no treatment; very low quality evidence).
In preventing gastric ulcer recurrence, eradication therapy was superior to no treatment (12 trials, 1476 participants, RR 0.31, 95%
CI 0.22 to 0.45; 116/697 (adjusted proportion: 16.3%) in eradication therapy versus 356/679 (52.4%) in no treatment; very low
quality evidence). None of the trials reported proportion of people with gastric ulcer not healed after initial therapy between H.pylori
eradication therapy and no active treatment or the proportion of people with recurrent gastric ulcer or peptic ulcers during maintenance
therapy between H.pylori eradication therapy and ulcer healing drug therapy.
Authors’ conclusions
Adding a one to two-week course of H. pylori eradication therapy is an effective treatment for people with H. pylori-positive duodenal
ulcer when compared to ulcer healing drugs alone and no treatment. H. pylori eradication therapy is also effective in preventing
recurrence of duodenal and gastric ulcer compared to no treatment. There is currently no evidence that H. pylori eradication therapy
is an effective treatment in people with gastric ulcer or that it is effective in preventing recurrence of duodenal ulcer compared to ulcer
healing drug. However, confidence intervals were wide and significant benefits or harms of H. pylori eradication therapy in acute ulcer
healing of gastric ulcers compared to no treatment, and in preventing recurrence of duodenal ulcers compared to ulcer healing drugs
cannot be ruled out.
P L A I N L A N G U A G E S U M M A R Y
Antibiotics for people with peptic ulcers caused by Helicobacter pylori infection
Review question
Are antibiotics useful for the treatment of peptic ulcer (ulcers in the stomach or upper small intestine) in people with Helicobacter pylori
(H. pylori) infection?
Background
Peptic ulcers are caused by acidic stomach juices damaging the lining of the stomach (gastric ulcer) or upper small intestine (duodenal
ulcer). This causes pain, indigestion and sometimes, bleeding. Ulcers can return after being healed, especially if the person is infected
with Helicobacter pylori (a lifelong infection unless treated). H. pylori causes most peptic ulcers. It is not clear whether eradicating
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H.pylori by treating with antibiotics as part of a combination of drugs (H.pylori eradication therapy) is helpful in the treatment of people
with peptic ulcers compared to no treatment or other medical treatments. This is an update of a previous Cochrane review published
in 2006.
Study characteristics
Fifty-five studies provided information for the review. Thirty-four studies compared H. pylori eradication therapy plus ulcer-healing
drug against ulcer-healing drug alone in the healing of duodenal ulcer. Two studies compared H. pylori eradication therapy against no
treatment in the healing of duodenal ulcer. Fifteen studies compared H. pylori eradication therapy plus ulcer-healing drug against ulcer-
healing drug alone in the healing of gastric ulcer. Three studies compared H. pylori eradication therapy plus ulcer-healing drug against
ulcer-healing drug alone in the healing of peptic ulcer (gastric or duodenal ulcer). One study compared H. pylori eradication therapy
against no treatment in the healing of peptic ulcer (gastric or duodenal ulcer). Four studies compared H. pylori eradication therapy
against ulcer-healing drug in preventing the recurrence of duodenal ulcer after initial ulcer had been healed. Twenty-seven studies
compared H. pylori eradication therapy against no treatment in preventing the recurrence of duodenal ulcer after initial ulcer had been
healed. Twelve studies compared H. pylori eradication therapy against no treatment in preventing the recurrence of gastric ulcer after
initial ulcer had been healed, while one study compared H. pylori eradication therapy against no treatment in preventing the recurrence
of peptic ulcer (gastric or duodenal ulcer) after initial ulcer had been healed. Four studies compared H. pylori eradication therapy plus
ulcer-healing drug versus comparison regimen in the relief of symptoms from peptic ulcer (gastric or duodenal ulcer). There were no
studies comparing H. pylori eradication therapy against no treatment in the healing of gastric ulcer, H. pylori eradication therapy against
ulcer-healing drug as maintenance therapy in preventing the recurrence of gastric ulcer after initial ulcer had been healed, or H. pylori
eradication therapy plus ulcer-healing drug against no treatment or ulcer-healing drug in the relief of symptoms in people with peptic
ulcer. Some trials provided information for more than one comparison. The evidence is current until March 2016.
Key results
Adding a one to two-week course of H. pylori eradication therapy speeds up ulcer healing for people with H. pylori-positive duodenal
ulcer when compared to ulcer-healing drugs alone and no treatment. H. pylori eradication therapy is also effective in preventing
recurrence of duodenal and gastric ulcer (ulcer returning after initial healing) compared to no treatment. There is currently no evidence
that H. pylori eradication therapy is an effective treatment in people with gastric ulcer or that it is effective in preventing recurrence of
duodenal ulcer compared to ulcer-healing drugs. However, because of the small number of studies included for the last two comparisons,
significant benefits or harms of H. pylori eradication therapy in acute ulcer healing of gastric ulcers compared to no treatment and in
preventing recurrence of duodenal ulcers compared to ulcer healing drugs cannot be ruled out.
Quality of the evidence
The quality of evidence was low or very low because most of the studies had errors in study design. As a result, there is a lot of uncertainty
regarding the results.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Additional Helicobacter pylori eradication therapy for acute ulcer healing in people with Helicobacter pylori-positive peptic ulcer
Patient or population: people with Helicobacter pylori-positive pept ic ulcer
Settings: secondary and tert iary care
Intervention: Addit ional Helicobacter pylori eradicat ion therapy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Control Additional Helicobacter py-
lori eradication therapy
Proportion of people with duodenal ulcer not healed after initial therapy
H. pylori eradicat ion therapy
plus ulcer healing drug ver-
sus ulcer healing drug alone
187 per 1000 124 per 1000
(109 to 142)
RR 0.66
(0.58 to 0.76)
3910
(34 studies)
⊕⊕©©
low1,2
H. pylori eradicat ion therapy
versus no act ive treatment
585 per 1000 217 per 1000
(152 to 310)
RR 0.37
(0.26 to 0.53)
207
(2 studies)
⊕⊕©©
low1,3
Proportion of people with gastric ulcer not healed after initial therapy
H. pylori eradicat ion therapy
plus ulcer healing drug ver-
sus ulcer healing drug alone
130 per 1000 160 per 1000
(117 to 219)
RR 1.23
(0.9 to 1.68)
1974
(15 studies)
⊕©©©
very low1,2,4,5
Proportion of people with peptic ulcer (gastric or duodenal ulcer) not healed after initial therapy
H. pylori eradicat ion therapy
plus ulcer healing drug ver-
sus ulcer healing drug alone
247 per 1000 129 per 1000
(77 to 210)
RR 0.52
(0.31 to 0.85)
287
(3 studies)
⊕⊕©©
low1,3
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H. pylori eradicat ion therapy
versus no act ive treatment
800 per 1000 120 per 1000
(40 to 360)
RR 0.15
(0.05 to 0.45)
40
(1 study)
⊕⊕©©
low1,3
None of the trials reported proport ion of people with gastric ulcer not healed af ter init ial therapy between H.pylori eradicat ion therapy and no act ive treatment.
* The basis for the assumed risk is the control group risk. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the comparison group and
the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 The risk of bias in trial(s) was high.
2 Possible small study ef fect/ publicat ion bias as suggested by funnel plot and tests for funnel plot asymmetry (Begg 1994;
Egger 1997).
3 The sample size was small.
4 There was moderate to signif icant heterogeneity as measured by I2 (Higgins 2003).
5 The conf idence intervals were wide.
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B A C K G R O U N D
Description of the condition
Peptic ulcer disease is common, with some 10% of the popula-
tion of Western countries likely to suffer a duodenal or gastric
ulcer during their lifetime (Dobrilla 1993). The annual estimated
national costs were USD 3.1 billion in United States, USD 29
to USD 94 million in Sweden in 1998 and USD 522 million in
France in 1987 (Barkun 2010). Those suffering from peptic ulcer
disease can be troubled by recurrent bouts of pain, in addition
to more serious consequences such as haemorrhage or perforation
(Penston 1993).
Until the recognition of the major role played by Helicobacter
pylori, the most important factors in the pathogenesis of peptic
ulcer disease were thought to be acid and pepsin damaging the
epithelial cells of the stomach and duodenum (Peterson 1990).
Description of the intervention
Triple therapy regimens (acid suppressing therapy combined with
two antibiotics aimed at eradicating H. pylori) given for one week
are said to achieve rapid symptom relief and healing rates of ap-
proximately 90% of duodenal ulcers and 85% of gastric ulcers,
with studies suggesting this is more effective than antisecretory
drugs alone (Penston 1996). Furthermore, people receiving suc-
cessful H. pylori eradication had a relapse rate of approximately
5% compared with 80% of those healed on histamine-2 receptor
antagonists (H2RAs) (Penston 1996).
Initially triple therapy was instituted using bismuth salts and an-
tibiotics, but subsequent trials replaced the bismuth with proton
pump inhibitors (PPI) and discovered that this was better toler-
ated, and achieved similar rates of eradication of H. pylori (Hunt
1997). Despite these advances, and numerous narrative reviews on
H. pylori eradication in peptic ulcer disease, we were not aware of
a recent systematic review evaluating duodenal and gastric ulcers
separately.
How the intervention might work
In the 1970s and 1980s therapy was mainly aimed at reducing
acid secretion, achieved by the use of H2RAs and PPIs (Feldman
1995). However in the late 1980s and early 1990s the importance
of H. pylori in ulcer development and recurrence was confirmed,
and it was postulated that this could be prevented by eradication
of this organism (Tytgat 1998), which is implicated in 90% to
95% of duodenal and approximately 70% of gastric ulcers.
Why it is important to do this review
The aim of this review was to conduct a systematic review of ran-
domised controlled trials to obtain a more precise estimate of the
efficacy of eradication therapy in the short- and long-term treat-
ment of H. pylori-positive individuals with peptic ulcer disease.
This is an update of a previous Cochrane review (Ford 2006). The
previous version concluded that a one to two-week course of H.
pylori eradication therapy is an effective treatment for H. pylori-
positive peptic ulcer disease. Since the search was outdated, it is
important to provide up-to-date evidence.
O B J E C T I V E S
To assess the proportion of peptic ulcers healed and the proportion
of participants who remained free from relapse with eradication
therapy against placebo or other pharmacological therapies in H.
pylori-positive people.
To assess the proportion of participants that achieved complete
relief of symptoms and improvement in quality of life scores.
To compare the incidence of adverse effects/drop-outs (total num-
ber for each drug) associated with the different treatments.
To assess the proportion of participants in whom successful erad-
ication was achieved.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Only randomised controlled trials looking at the short- and long-
term treatment of peptic ulcer disease were eligible for inclusion
in this review. We also included the first period of cross-over trials.
Types of participants
All participants recruited in the trials analysedwere adults who had
peptic ulcer diagnosed at endoscopy or on barium meal and who
had H. pylori status confirmed positive on either serology, CLO
test, urease breath test, biopsy or a combination of these tests.
Types of interventions
The tested drug had to fall within the following drug class 1, the
comparison regimen also had to be one of 2 to 9 from the list
below.
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1. Efficacious eradication therapy: we defined this as a
regimen reported in the literature that usually achieves at least a
50% eradication rate, and this included;
i) PPI dual therapy (PPI plus either amoxicillin or
clarithromycin)
ii) PPI triple therapy (PPI plus two of the following;
amoxicillin, macrolide, 5 nitroimidazole)
iii) H2RA triple therapy (H2RA plus two of the
following; amoxicillin, macrolide, 5 nitroimidazole)
iv) Bismuth triple therapy (bismuth salt and 5
nitroimidazole with either amoxicillin or tetracycline)
v) Bismuth quadruple therapy (as bismuth triple therapy,
but PPI in addition)
vi) Ranitidine bismuth citrate dual/triple therapy (as for
PPI)
vii) Clarithromycin monotherapy
2. PPIs: esomeprazole, lansoprazole, omeprazole,
pantoprazole, rabeprazole.
3. H2RAs: cimetidine, famotidine, nizatidine, ranitidine.
4. Bismuth salts.
5. Sucralfate.
6. Regular antacid.
7. Antacid as needed (PRN).
8. Placebo.
9. No treatment.
Participants had to have had at least one week of therapy.
Types of outcome measures
Trials were included if they reported evidence of assessment from
two weeks onwards.
The following outcomes were included in this review.
Primary outcomes
1. Proportion of peptic ulcers healed after initial therapy.
2. Proportion of participants with peptic ulcer that remained
free from relapse following successful ulcer healing.
3. Proportion of participants that achieved complete relief
from symptoms of peptic ulcer.
Secondary outcomes
1. Recording of adverse effects of the pharmacological
interventions.
2. H. pylori eradication rates.
3. Improvement in quality of life (QoL) scores.
Search methods for identification of studies
We conducted searches to identify all published and unpublished
randomised controlled trials. Articles published in any language
were included.
Electronic searches
We identified trials by searching the Cochrane Central Register of
Controlled Trials (CENTRAL) via Wiley (Appendix 1), MED-
LINE (1950 to March 2016) via OvidSP (Appendix 2) and EM-
BASE (1980 to March 2016) via OvidSP (Appendix 3). We did
not confine our search to English language publications. Searches
in all databases were updated in September 2003,November 2004,
November 2005, July 2008, August 2010, January 2015, and
March 2016. The Cochrane Highly Sensitive Search Strategy for
identifying randomised trials in MEDLINE, sensitivity-maximis-
ing version, Ovid format (Lefebvre 2011) was combined with
search terms to identify randomised controlled trials in MED-
LINE (Appendix 2). The MEDLINE search strategy (please see
Appendix 2) was adapted for use in the other databases searched.
Searching other resources
We handsearched reference lists from trials selected by electronic
searching to identify further relevant trials.
Abstracts
We handsearched Digestive Disease Week (DDW) (published in
Gastroenterology) and United European Gastroenterology Week
(UEGW) (published in Gut) abstract books between 1994 and
2003. We contacted authors of trial reports published only as
abstracts and asked them to contribute full data sets or completed
papers.
Correspondence
We contacted experts in the field registered with the Cochrane
Upper GI and Pancreatic Diseases (UGPD) review group for leads
on unpublished studies. In addition, we contacted the following
pharmaceutical companies - Abbott-Knoll, Astra-Zeneca, Eisai,
Glaxo-Smithkline, Lilly and Wyeth and asked them to supply
details of any outstanding clinical trials and relevant unpublished
materials.
We contacted the following experts in the field:
1. Dr. Franco Bazzoli, Università di Medicina Interna e
Gastroenterologica, Bologna, Italy
2. Dr. Cathy Bennett, North Yorkshire Cancer Registry,
Leeds, UK
3. Dr. Xavier Calvet, Corporacio Sanitaria del Park Tau,
Sabell, Spain
4. Dr. Naoki Chiba, Guelph, Canada
5. Dr. C Fallone, McMaster University Medical Centre,
Hamilton, Canada
6. Dr. Lori Fischbach, University of Texas, Dallas, USA
7. Dr. Javier P Gisbert, University Hospital de la Princesa,
Madrid, Spain
8. Dr. Adam Harris, Kent and Sussex Hospitals, Tunbridge
Wells, UK
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9. Professor Richard Hunt, McMaster University Medical
Centre, Hamilton, Canada
10. Dr. J Huang, McMaster University Medical Centre,
Hamilton, Canada
11. Professor Ernst J Kuipers, Free University Hospital,
Amsterdam, Netherlands
12. Dr. Robert Laheij, Dept. of Gastroenterology, Nijmegen,
Netherlands
13. Professor Francis Megraud, Hôpital Pellegrin, Bordeaux,
France
14. Dr. D Palli, Epidemiology Unit CSPO, Florence, Italy
15. Dr. V Savarino, Università di Genova, Genova, Italy
16. Dr. P Unge, Gävle, Sweden
Data collection and analysis
Selection of studies
The lead review author screened titles and trial abstracts that had
been identified by the search strategy for articles that could possibly
be eligible for the review. A second review author independently
checked a sample of this selection process.
The lead review author then screened the full article of selected
trials to confirm eligibility, using pre-designed eligibility forms. A
second review author, masked to the initial assessment, also eval-
uated all full articles for eligibility. A third review author adjudi-
cated any discrepancies and a consensus view was taken.
Data extraction and management
Data were extracted by the lead review author and recorded onto
specially developed forms. There was an unblinded check on this
by a second review author.We also double-checked data entry into
RevMan (RevMan 2014).
The following characteristics were recorded for each trial
1. Setting: primary or secondary care
2. Country of origin
3. Inclusion and exclusion criteria used
4. Baseline comparability between treatment groups
5. Treatments compared and number of participants in each
arm
6. Drop-outs reported and their reasons
7. Site of ulcer
8. Ulcer healing rates
9. Ulcer recurrence rates
10. Complication rates
11. Eradication rates
12. Type of eradication regimen
13. Names, dosage, and schedule of drugs
14. Adverse events: the total and individual numbers reported
15. Quality of life
16. Global symptoms cured or recurred
We extracted data as intention-to-treat analyses, where we con-
sidered that the treatment had failed in all participants who were
excluded from analysis.
Assessment of risk of bias in included studies
Two review authors assessed the risk of bias for each study inde-
pendently using the criteria outlined in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011) and resolved
any disagreement by discussion. We assessed the risk of bias ac-
cording to the following domains:
1. random sequence generation;
2. allocation concealment;
3. blinding of participants, personnel and outcome assessors;
4. incomplete outcome data;
5. selective outcome reporting;
6. other bias.
We graded each potential source of bias as high, low or unclear and
provided a quote from the study report together with a justification
for our judgement in the ’Risk of bias’ table. We summarised the
risk of bias judgements across different studies for each of the
domains listed.
Measures of treatment effect
We combined risk ratios (RR) for binary outcomes. We calculated
the number needed to treat for an additional beneficial outcome
(NNTB) or number needed to treat for an additional harmful
outcome (NNTH) as the inverse of the risk difference from the
meta-analysis.
Dealing with missing data
Completeness of follow-up and intention-to-treat analysis
Where possible, we recorded completeness of follow-up, intention-
to-treat analysis and drop-out rates by group.
Assessment of heterogeneity
We explored reasons for heterogeneity according to the following
predefined criteria.
1. Multi-centre versus single-centre
2. Country of origin
3. Mean age of participants included in the study
4. Method of randomisation
5. Method of concealment of allocation
6. Masking versus no masking
7. Type of eradication regimen
8. H. pylori eradication rate
9. Duration of treatment
10. Completeness of follow-up
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We used the I² statistic to measure heterogeneity among the trials
in each analysis (Higgins 2003).
Assessment of reporting biases
If we were able to pool more than 10 trials, we created and exam-
ined a funnel plot to explore possible publication biases. We used
Egger’s test (Egger 1997) and Begg’s test (Begg 1994) to determine
the statistical significance of the reporting bias. A P value of less
than 0.10 was considered statistically significant reporting bias.
Data synthesis
For binary outcomes, such as peptic ulcer healing, peptic ulcer
recurrence and absence of symptoms, we expressed the impact of
interventions as risk ratios (RR) together with 95% confidence
intervals (CI). We analysed the data for gastric ulcer and duodenal
ulcer, and for short- and long-term treatment, separately wherever
possible. We also analysed the comparison regimens separately.
There was sufficient data for the generation of a meta-analysis for
this review.
Subgroup analysis and investigation of heterogeneity
Where significant (P < 0.1) heterogeneity was detected, we inves-
tigated possible explanations informally, and summarised the data
using a random-effects analysis.
R E S U L T S
Description of studies
Results of the search
In total, we identified 3585 citations using the search strategy
outlined above.We reviewed the titles and abstracts and selected 85
papers which compared a recognisedH. pylori eradication regimen
against placebo or other pharmacological therapies in H. pylori-
positive peptic ulcer disease. Twenty-five studies (26 reports) did
not meet the eligibility criteria and were excluded (Characteristics
of excluded studies). A total of 55 trials (59 references) provided
data for one or more comparisons and outcomes for this review
(see Effects of interventions). The reference flow is shown in Figure
1.
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Figure 1. Study flow diagram.
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Included studies
Please see Characteristics of included studies.
H. pylori eradication therapy plus ulcer-healing drug
versus ulcer-healing drug alone in the healing of
duodenal ulcer
Thirty-four RCTs (Asaka 2001; Avsar 1996; Bardhan 1997;
Bayerdorffer 1992; Bayerdorffer 1995; Bianchi Porro 1993;
Bianchi Porro 1996; Carpintero 1997; Figueroa 1996; Furuta
1995; Graham 1991; Graham 1998; Harford 1996; Hentschel
1993; Hosking 1992; Kato 1996; Katoh 1995; Kepecki 1999;
Lin 1994; Logan 1995; Mantzaris 1993; Mones 2001; O’Morain
1996; Parente 1996; Pinero 1995; Pounder 1997; Rauws 1990;
Schwartz 1998; Shirotani 1996; Sobhani 1995; Spinzi 1994; Van
Zanten 1999; Wang 1993; Wong 1999) with a total of 3910 par-
ticipants which comprised:
• nine RCTs (Bayerdorffer 1992; Bayerdorffer 1995; Furuta
1995; Harford 1996; Kato 1996; Katoh 1995; Logan 1995;
O’Morain 1996; Spinzi 1994) comparing PPI dual therapy with
ulcer-healing drug alone;
• eight RCTs (Avsar 1996; Bianchi Porro 1993; Graham
1991; Lin 1994; Mantzaris 1993; Pinero 1995; Rauws 1990;
Wang 1993) comparing bismuth triple therapy with ulcer-
healing drug alone;
• five RCTs (Asaka 2001; Bianchi Porro 1996; Kepecki 1999;
Mones 2001; Van Zanten 1999) comparing PPI triple therapy
with ulcer-healing drug alone;
• three RCTs (Hentschel 1993; Shirotani 1996; Sobhani
1995) comparing H2RA triple therapy with ulcer-healing drug
alone;
• three RCTs (Bardhan 1997; Graham 1998; Pounder 1997)
comparing ranitidine bismuth citrate dual therapy with ulcer-
healing drug alone;
• two RCTs (Figueroa 1996; Hosking 1992) comparing
bismuth quadruple therapy with ulcer-healing drug alone;
• one RCT (Parente 1996) comparing bismuth quadruple
therapy and PPI dual therapy with ulcer-healing drug alone;
• one RCT (Carpintero 1997) comparing bismuth triple
therapy and H2RA triple therapy with ulcer-healing drug alone;
• one RCT (Schwartz 1998) comparing PPI triple and dual
therapy with ulcer-healing drug alone;
• one RCT (Wong 1999) comparing clarithromycin
monotherapy with ulcer-healing drug alone.
There were 14 multi-centre trials. The smallest RCT included 32
participants. The largest RCT included 352 participants.
H. pylori eradication therapy versus no treatment in
the healing of duodenal ulcer
Two RCTs (Graham 1998; Lam 1997) with a total of 207 partic-
ipants which comprised:
• one multi-centre RCT (Graham 1998) comparing
ranitidine bismuth citrate dual therapy with no treatment;
• one RCT (Lam 1997) comparing clarithromycin
monotherapy with no treatment.
H. pylori eradication therapy plus ulcer-healing drug
versus ulcer-healing drug alone in the healing of
gastric ulcer
Fifteen RCTs (Asaka 2001; Axon 1997; Bayerdorffer 1996; Befrits
2004; Fukuda 1995a; Fukuda 1995b; Furuta 1995;Higuchi 2003;
Kato 1996; Katoh 1995; Lazzaroni 1997; Malfertheiner 1999;
Meining 1998; Sung 1995; Tulassay 2008) with a total of 1974
participants which comprised:
• eight RCTs (Axon 1997; Fukuda 1995a; Fukuda 1995b;
Furuta 1995; Kato 1996; Katoh 1995; Lazzaroni 1997; Meining
1998) comparing PPI dual therapy with ulcer-healing drug alone;
• two RCTs (Bayerdorffer 1996; Sung 1995) comparing
bismuth triple therapy with ulcer-healing drug alone;
• five RCTs (Asaka 2001; Befrits 2004; Higuchi 2003;
Malfertheiner 1999; Tulassay 2008) comparing PPI triple
therapy with ulcer-healing drug alone.
There were seven multi-centre trials. The smallest trial included
27 participants. The largest trial included 402 participants.
H. pylori eradication therapy versus no treatment in
the healing of gastric ulcer
No RCTs were identified.
H. pylori eradication therapy plus ulcer-healing drug
versus ulcer-healing drug alone in the healing of
peptic ulcer
Three RCTs (Arkkila 2005; Suarez 1999;Wang 1996) with a total
of 287 participants which comprised:
• one RCT (Arkkila 2005) comparing bismuth quadruple
therapy, PPI triple therapy, and PPI dual therapy with ulcer-
healing drug alone;
• one RCT (Wang 1996) comparing bismuth triple therapy
and PPI dual therapy with ulcer-healing drug alone;
• one RCT (Suarez 1999) comparing bismuth triple therapy
with ulcer-healing drug alone.
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H. pylori eradication therapy versus no treatment in
the healing of peptic ulcer
One single-centre RCT (Feng 2005) with a total of 40 participants
comparing PPI triple therapy with no treatment.
H. pylori eradication therapy versus ulcer-healing
drug as maintenance therapy in preventing the
recurrence of duodenal ulcer (after initial ulcer had
been healed)
Four RCTs (Kepecki 1999; Mones 2001; Sobhani 1995; Wong
1999) with a total of 319 participants which comprised:
• two RCTs (Kepecki 1999; Mones 2001) comparing PPI
triple therapy with ulcer-healing drug alone;
• one RCT (Sobhani 1995) comparing H2RA triple therapy
with ulcer-healing drug alone;
• one RCT (Wong 1999) comparing clarithromycin
monotherapy with ulcer-healing drug alone.
There were two multi-centre trials: the smallest trial included 73
participants, the largest trial included 119 participants.
H. pylori eradication therapy versus no treatment in
preventing the recurrence of duodenal ulcer (after
initial ulcer had been healed)
Twenty-seven RCTs (Avsar 1996; Bardhan 1997; Bayerdorffer
1992; Bayerdorffer 1995; Bianchi Porro 1996; Carpintero 1997;
Chen 1995; Figueroa 1996; Graham 1992; Hentschel 1993;
Hosking 1992; Kato 1996; Kim 2002; Lin 1994; Logan 1995;
Mantzaris 1993; O’Morain 1996; Pinero 1995; Pounder 1997;
Rauws 1990; Schwartz 1998; Shirotani 1996; Spinzi 1994; Tomita
2002; Unge 1993; Van Zanten 1999; Wang 1993) with a total of
2509 participants which comprised:
• eight RCTs (Avsar 1996; Chen 1995; Graham 1992; Lin
1994; Mantzaris 1993; Pinero 1995; Rauws 1990; Wang 1993)
comparing bismuth triple therapy with no treatment;
• seven RCTs (Bayerdorffer 1992; Bayerdorffer 1995; Kato
1996; Logan 1995; O’Morain 1996; Spinzi 1994; Unge 1993)
comparing PPI dual therapy with no treatment;
• four RCTs (Bianchi Porro 1996; Kim 2002; Tomita 2002;
Van Zanten 1999) comparing PPI triple therapy with no
treatment;
• two RCTs (Hentschel 1993; Shirotani 1996) comparing
H2RA triple therapy with no treatment;
• two RCTs (Bardhan 1997; Pounder 1997) comparing
ranitidine bismuth citrate dual therapy with no treatment;
• two RCTs (Figueroa 1996; Hosking 1992) comparing
bismuth quadruple therapy with no treatment;
• one RCT (Schwartz 1998) comparing PPI triple and dual
therapy with no treatment;
• one RCT (Carpintero 1997) comparing bismuth triple
therapy and H2RA triple therapy with no treatment.
There were nine multi-centre trials: the smallest trial contained 20
participants, the largest trial contained 233 participants.
H. pylori eradication therapy versus ulcer-healing
drug as maintenance therapy in preventing the
recurrence of gastric ulcer (after initial ulcer had
been healed)
No RCTs were identified.
H. pylori eradication therapy versus no treatment in
preventing the recurrence of gastric ulcer (after
initial ulcer had been healed)
Twelve RCTs (Axon 1997; Bayerdorffer 1996; Befrits 2004;
Fukuda 1995b; Graham 1992; Kato 1996; Lazzaroni 1997;
Malfertheiner 1999; Meining 1998; Sung 1995; Tomita 2002;
Tulassay 2008) with a total of 1476 participants which comprised:
• five RCTs (Axon 1997; Fukuda 1995b; Kato 1996;
Lazzaroni 1997; Meining 1998) comparing PPI dual therapy
with no treatment;
• three RCTs (Bayerdorffer 1996; Graham 1992; Sung 1995)
comparing bismuth triple therapy with no treatment;
• four RCTs (Befrits 2004; Malfertheiner 1999; Tomita 2002;
Tulassay 2008) comparing PPI triple therapy with no treatment.
There were six multi-centre trials. The smallest trial contained 59
participants. The largest trial contained 372 participants.
H. pylori eradication therapy versus ulcer-healing
drug as maintenance therapy in preventing the
recurrence of peptic ulcer (after initial ulcer had been
healed)
No RCTs were identified.
H. pylori eradication therapy versus no treatment in
preventing the recurrence of peptic ulcer (after initial
ulcer had been healed)
One RCT (Arkkila 2005) with a total of 103 participants compar-
ing bismuth quadruple therapy, PPI triple therapy, and PPI dual
therapy with no treatment.
H. pylori eradication therapy plus ulcer-healing drug
versus comparison regimen in the relief of symptoms
from peptic ulcer
Four RCTs (Higuchi 2003; Lam 1997; Pounder 1997; Suarez
1999) with a total of 368 participants which comprised:
• one RCT (Higuchi 2003) comparing PPI triple therapy
with ulcer-healing drug alone
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• one RCT (Lam 1997) comparing clarithromycin
monotherapy with no treatment
• one RCT (Pounder 1997) comparing ranitidine bismuth
citrate dual therapy with no treatment
• one RCT (Suarez 1999) comparing bismuth triple therapy
with ulcer-healing drug alone
H. pylori eradication therapy plus ulcer-healing drug
versus comparison regimen and improvement in
quality of life scores in people with peptic ulcer
patients
No RCTs were identified.
Excluded studies
Please see Characteristics of excluded studies.
We excluded:
• seven studies because they were non-randomised studies
(Kohli 1995; Nakata 1995; O’Riordan 1990; Parente 1998;
Shimoyama 1995; Sugiyama 1995; Xia 1995);
• two studies since not all participants were H. pylori-positive,
and separate data was not available for H. pylori-positive
participants (Bytzer 2000; Peterson 1996);
• one study because participants in control arm were H. pylori
-negative (Dogan 1997);
• two studies since not all participants had documented
peptic ulcer disease (Prach 1998; Veldhuyzen Van Zanten 2000);
• two studies (three references) since the participants did not
have peptic ulcer disease (Dumbleton 2015; Tham 1996);
• one study since the eradication regimen used was not a
recognised regimen (Rune 1993);
• one study since there was no comparison arm (Hosking
1994);
• nine studies since there was no ulcer healing or recurrence
data (Al-Assi 1995; Gisbert 2000; Labenz 1993; Laine 2000;
Lind 1996; Malfertheiner 2002a; Sonnenberg 1998; Sonnenberg
1999; Tavakoli 1999).
Risk of bias in included studies
Two authors undertook an assessment of the risk of bias of each
eligible study independently. Methods of randomisation, conceal-
ment, and masking were assessed (Higgins 2011). A summary of
the risk of bias may be found in Figure 2 and Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Twelve trials stated the method of random sequence genera-
tion (Arkkila 2005; Axon 1997; Bianchi Porro 1993; Carpintero
1997; Higuchi 2003; Hosking 1992; Kim 2002; Lazzaroni 1997;
Meining 1998; Mones 2001; Sung 1995; Tulassay 2008) and five
trials reported themethod of allocation concealment (Bayerdorffer
1996; Higuchi 2003; Hosking 1992; Meining 1998; Sung 1995).
Four trials reported the random sequence generation and alloca-
tion concealment andwere free from selection bias (Higuchi 2003;
Hosking 1992; Meining 1998; Sung 1995).
Blinding
Blinding was performed in 36 trials (Arkkila 2005; Asaka 2001;
Avsar 1996; Axon 1997; Bardhan 1997; Bayerdorffer 1992;
Bayerdorffer 1995; Bayerdorffer 1996; Befrits 2004; Feng 2005;
Figueroa 1996; Fukuda 1995b; Graham 1991; Graham 1992;
Graham 1998; Harford 1996; Hentschel 1993; Higuchi 2003;
Hosking 1992; Kim 2002; Lam 1997; Lazzaroni 1997; Logan
1995; Malfertheiner 1999; Mantzaris 1993; Meining 1998;
Mones 2001; O’Morain 1996; Pounder 1997; Schwartz 1998;
Shirotani 1996; Sobhani 1995; Tulassay 2008; Unge 1993; Van
Zanten 1999; Wong 1999) and were free from performance bias
and detection bias.
Incomplete outcome data
Fifteen trials included all participants in the analysis and were
free from attrition bias (Avsar 1996; Bianchi Porro 1993; Graham
1992; Harford 1996; Kato 1996; Katoh 1995; Lam 1997;
Lazzaroni 1997; Logan 1995; Mantzaris 1993; Meining 1998;
O’Morain 1996; Shirotani 1996; Suarez 1999; Wong 1999).
Selective reporting
Thirty-three trials reported the outcomes collected and were
free from selective outcome reporting bias (Asaka 2001; Axon
1997; Bardhan 1997; Bayerdorffer 1996; Bianchi Porro 1993;
Bianchi Porro 1996; Carpintero 1997; Figueroa 1996; Fukuda
1995b; Furuta 1995; Harford 1996; Higuchi 2003; Hosking
1992; Kato 1996; Katoh 1995; Kepecki 1999; Kim 2002; Lam
1997; Lin 1994; Malfertheiner 1999; O’Morain 1996; Parente
1996; Pounder 1997; Rauws 1990; Schwartz 1998; Shirotani
1996; Sobhani 1995; Spinzi 1994; Suarez 1999; Tulassay 2008;
Unge 1993; Van Zanten 1999; Wang 1996).
Other bias
Fifty-two trials were free from other bias (Asaka 2001; Avsar 1996;
Axon 1997; Bardhan 1997; Bayerdorffer 1992; Bayerdorffer 1995;
Bayerdorffer 1996; Befrits 2004; Bianchi Porro 1996; Carpintero
1997; Chen 1995; Feng 2005; Figueroa 1996; Fukuda 1995a;
Fukuda 1995b; Furuta 1995; Graham 1991; Graham 1992;
Graham 1998; Harford 1996; Hentschel 1993; Higuchi 2003;
Hosking 1992;Kato 1996;Katoh 1995;Kepecki 1999;Kim2002;
Lam 1997; Lazzaroni 1997; Lin 1994; Logan 1995;Malfertheiner
1999; Mantzaris 1993; Meining 1998; Mones 2001; O’Morain
1996; Parente 1996; Pinero 1995; Pounder 1997; Rauws 1990;
Schwartz 1998; Shirotani 1996; Sobhani 1995; Spinzi 1994;
Suarez 1999; Sung1995;Tomita 2002;Tulassay 2008;Unge 1993;
Van Zanten 1999; Wang 1993; Wong 1999).
Effects of interventions
See: Summary of findings for the main comparison Additional
Helicobacter pylori eradication therapy for acute ulcer healing in
people with Helicobacter pylori-positive peptic ulcer; Summary
of findings 2 Additional Helicobacter pylori eradication therapy
for prevention of recurrence in people with Helicobacter-positive
peptic ulcer
In dealing with the results obtained in this review we will, for
the sake of clarity, consider them in the following order; firstly
ulcer healing, secondly prevention of ulcer recurrence after initial
healing, thirdly relief of symptoms of peptic ulcer, and finally side
effects.
Ulcer healing
H. pylori eradication therapy plus ulcer-healing drug versus
ulcer-healing drug alone in the healing of duodenal ulcer
Thirty-four RCTs (Asaka 2001; Avsar 1996; Bardhan 1997;
Bayerdorffer 1992; Bayerdorffer 1995; Bianchi Porro 1993;
Bianchi Porro 1996; Carpintero 1997; Figueroa 1996; Furuta
1995; Graham 1991; Graham 1998; Harford 1996; Hentschel
1993; Hosking 1992; Kato 1996; Katoh 1995; Kepecki 1999;
Lin 1994; Logan 1995; Mantzaris 1993; Mones 2001; O’Morain
1996; Parente 1996; Pinero 1995; Pounder 1997; Rauws 1990;
Schwartz 1998; Shirotani 1996; Sobhani 1995; Spinzi 1994; Van
Zanten 1999; Wang 1993; Wong 1999) reported a dichotomous
duodenal ulcer healing outcome evaluating 3910 participants, be-
tween one and four months. Overall 17% of duodenal ulcers re-
mained unhealed in theH. pylori eradication group comparedwith
19% in the ulcer-healing drug group. There was no statistically
significant heterogeneity between the trial results (heterogeneity
test (32 degrees of freedom) Chi2 statistic = 36.30, P = 0.27).
There was a small but statistically significant benefit of H. pylori
eradication therapy plus ulcer-healing drug compared to ulcer-
healing drug alone in the healing of duodenal ulcer (relative risk of
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ulcer persisting with H. pylori eradication therapy plus ulcer-heal-
ing drug versus ulcer-healing drug alone (RR 0.66, 95% CI 0.58
to 0.76; Analysis 1.1) (NNTB = 14; 95% CI 11 to 20). Egger test
revealed funnel plot asymmetry (P = 0.02) with a preponderance
of trials with few events showing large effects when 1/standard
error was used as a measure of study size (Figure 4).
Figure 4. Funnel plot of comparison: 1 H. pylori eradication + ulcer-healing drug vs. ulcer-healing drug
alone: duodenal ulcer acute healing, outcome: 1.1 Proportion not healed.
H. pylori eradication therapy versus no treatment in the
healing of duodenal ulcer
Two RCTs (Graham 1998; Lam 1997) reported a dichotomous
duodenal ulcer healing outcome evaluating 207 participants, be-
tween two and three months. Overall 24% of duodenal ulcers
remained unhealed in the H. pylori eradication group compared
with 58.5% in the no treatment group. There was no statistically
significant heterogeneity between the trial results (heterogeneity
test (1 degree of freedom) Chi2 statistic = 0.02, P = 0.88). There
was a statistically significant benefit of H. pylori eradication ther-
apy plus ulcer-healing drug compared to no treatment in the heal-
ing of duodenal ulcer (RR 0.37, 95% CI 0.26 to 0.53; Analysis
2.1) (NNTB 2.5; 95% CI 2 to 4).
H. pylori eradication therapy plus ulcer-healing drug versus
ulcer-healing drug alone in the healing of gastric ulcer
Fifteen RCTs (Asaka 2001; Axon 1997; Bayerdorffer 1996; Befrits
2004; Fukuda 1995a; Fukuda 1995b; Furuta 1995;Higuchi 2003;
Kato 1996; Katoh 1995; Lazzaroni 1997; Malfertheiner 1999;
Meining 1998; Sung 1995; Tulassay 2008) reported a dichoto-
mous gastric ulcer healing outcome evaluating 1974 participants,
between one and three months. Overall 18% of gastric ulcers re-
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mained unhealed in the H. pylori eradication group compared
with 13% in the ulcer-healing drug group. There was statistically
significant heterogeneity between the trial results (heterogeneity
test (14 degrees of freedom) Chi2 statistic = 22.93, P = 0.06) and
a random-effects model was used. There was no statistically sig-
nificant benefit of H. pylori eradication therapy plus ulcer-healing
drug compared to ulcer-healing drug alone in the healing of gas-
tric ulcer (RR 1.23, 95% CI 0.90 to 1.68; Analysis 3.1). There
was no evidence of funnel plot asymmetry (Egger test P = 0.39).
Metaregression was performed to evaluate whether length of treat-
ment in the control group, duration of eradication therapy, erad-
ication rate, length of follow-up, number of centres, method of
randomisation, concealment of allocation, blinding, intention-to-
treat analysis and completeness of follow-up had any impact on
the result that could explain some of the heterogeneity observed.
This suggested that multi-centre studies (log RR 1.52; 95% CI
0.87 to 2.18. P < 0.001), absence of blinding (log RR = 3.17; 95%
CI 1.53 to 4.82. P < 0.001), and a greater than 10% difference
in follow-up between trial arms (log RR = 3.09; 95% CI 0.82
to 5.37. P = 0.008) increased the effect size whereas performing
an intention-to-treat analysis (log RR = -1.55; 95% CI -0.38 to -
2.72. P = 0.01), and increasing completeness of follow-up (log RR
= -8.79; 95% CI -4.31 to -13.26. P < 0.001) reduced the effect
size.
H. pylori eradication therapy plus ulcer-healing drug versus
ulcer-healing drug alone in the healing of peptic ulcer
Three RCTs (Arkkila 2005; Suarez 1999; Wang 1996) reported
a dichotomous peptic ulcer healing outcome evaluating 287 par-
ticipants, between one and two months. Overall 12% of peptic
ulcers remained unhealed in theH. pylori eradication group com-
pared with 25% in the ulcer-healing drug group. There was no
statistically significant heterogeneity between trial results (hetero-
geneity test (2 degrees of freedom) Chi2 statistic = 3.31, P = 0.19).
There was a statistically significant benefit of H. pylori eradication
therapy plus ulcer-healing drug compared to ulcer-healing drug
alone in the healing of peptic ulcer (RR 0.52, 95% CI 0.31 to
0.85; Analysis 4.1) (NNTB = 8; 95% CI 4.5 to 50).
H. pylori eradication therapy versus no treatment in the
healing of peptic ulcer
One RCT (Feng 2005) reported a dichotomous peptic ulcer heal-
ing outcome evaluating 40 participants, at 1 month. Overall 12%
of peptic ulcers remained unhealed in the H. pylori eradication
therapy group compared with 80% in the no treatment group.
There was a statistically significant benefit of H. pylori eradication
therapy group compared to no treatment in the healing of peptic
ulcer (RR 0.15; 95% CI 0.05 to 0.45; Analysis 5.1) (NNTB =
1.5; 95% CI 1.1 to 2.3).
Preventing ulcer recurrence after initial ulcer healing
H. pylori eradication therapy versus ulcer-healing drug as
maintenance therapy in preventing the recurrence of
duodenal ulcer (after initial ulcer had been healed)
Four RCTs (Kepecki 1999; Mones 2001; Sobhani 1995; Wong
1999) reported a dichotomous duodenal ulcer recurrence outcome
evaluating 319 participants, between six months and two years.
Overall 12% of duodenal ulcers recurred in the H. pylori eradica-
tion group compared with 16% in the ulcer-healing drug as main-
tenance group. There was no statistically significant heterogeneity
between trial results (heterogeneity test (3 degrees of freedom) Chi
2 statistic = 3.22, P = 0.36). There was no statistically significant
benefit of H. pylori eradication therapy compared to ulcer-healing
drug as maintenance therapy in the prevention of duodenal ulcer
recurrence (relative risk of ulcer recurring after H. pylori eradica-
tion therapy versus maintenance anti-secretory therapy (RR 0.73;
95% CI 0.42 to 1.25; Analysis 6.1).
H. pylori eradication therapy versus no treatment in
preventing the recurrence of duodenal ulcer (after initial
ulcer had been healed)
Twenty-seven RCTs (Avsar 1996; Bardhan 1997; Bayerdorffer
1992; Bayerdorffer 1995; Bianchi Porro 1996; Carpintero 1997;
Chen 1995; Figueroa 1996; Graham 1992; Hentschel 1993;
Hosking 1992; Kato 1996; Kim 2002; Lin 1994; Logan 1995;
Mantzaris 1993; O’Morain 1996; Pinero 1995; Pounder 1997;
Rauws 1990; Schwartz 1998; Shirotani 1996; Spinzi 1994; Tomita
2002; Unge 1993; Van Zanten 1999; Wang 1993) reported a di-
chotomous duodenal ulcer recurrence outcome evaluating 2509
participants, between two months and five years. Overall 14% of
duodenal ulcers recurred in the H. pylori eradication group com-
pared with 64% in the no treatment group. There was statisti-
cally significant heterogeneity between trial results (heterogeneity
test (26 degrees of freedom) Chi2 statistic = 85.11, P < 0.00001)
and a random-effects model was used. There was a statistically
significant benefit of H. pylori eradication therapy compared to
no treatment in the prevention of duodenal ulcer recurrence (RR
0.20; 95% CI 0.15 to 0.26; Analysis 7.1) (NNTB = 2; 95% CI
1.6 to 2.2). Egger test revealed funnel plot asymmetry (P < 0.001)
with a preponderance of trials with few events showing large ef-
fects when 1/standard error was used as a measure of study size
(Figure 5). This statistically significant asymmetry was less marked
if the sample size was used as the measure of study size (P = 0.04).
Metaregression was performed to evaluate whether length of treat-
ment in the control group, duration of eradication therapy, erad-
ication rate, length of follow-up, number of centres, method of
randomisation, concealment of allocation, blinding, intention-to-
treat analysis and completeness of follow-up had any impact on
the result that could explain some of the heterogeneity observed.
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This revealed that the relative risk of recurrence reduced with in-
creasing eradication rate (log RR = -1.80; 95% CI -0.81 to -2.80.
P < 0.001) and duration of eradication therapy (log RR = -0.38;
95% CI -0.27 to -0.50. P < 0.001) and increased with increasing
length of follow-up (log RR = 0.006; 95% CI 0.001 to 0.010.
P = 0.02) and when an intention-to-treat analysis was performed
by the review authors (log RR = 0.31; 95% CI 0.11 to 0.52. P =
0.003).
Figure 5. Funnel plot of comparison: 7 H. pylori eradication vs. no treatment (after initial ulcer healing):
duodenal ulcer recurrence, outcome: 7.1 Proportion recurred.
H. pylori eradication therapy versus no treatment in
preventing the recurrence of gastric ulcer (after initial ulcer
had been healed)
Twelve RCTs (Axon 1997; Bayerdorffer 1996; Befrits 2004;
Fukuda 1995b; Graham 1992; Kato 1996; Lazzaroni 1997;
Malfertheiner 1999; Meining 1998; Sung 1995; Tomita 2002;
Tulassay 2008) reported a dichotomous gastric ulcer recurrence
outcome evaluating 1476 participants, between three months and
five years. Overall 15% of gastric ulcers recurred in the H. pylori
eradication group compared with 52% in the no treatment group.
There was statistically significant heterogeneity between trial re-
sults (heterogeneity test (11 degrees of freedom) Chi2 statistic =
29.09, P = 0.002) and a random effects model was used. There
was a statistically significant benefit of H. pylori eradication ther-
apy compared to no treatment in the prevention of gastric ulcer
recurrence (RR 0.31; 95% CI 0.22 to 0.45; Analysis 8.1) (NNTB
= 3; 95% CI 2 to 5). Egger test revealed a trend towards funnel
plot asymmetry (P = 0.07) with a preponderance of trials with few
events showing large effects when 1/standard error was used as a
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measure of study size (Figure 6). Metaregression was performed to
evaluate whether length of treatment in the control group, dura-
tion of eradication therapy, eradication rate, length of follow-up,
number of centres, method of randomisation, concealment of al-
location, blinding, intention-to-treat analysis and completeness of
follow-up had any impact on the result that could explain some of
the heterogeneity observed. This revealed that only concealment
of allocation had any impact on effect size (RR of recurrence in-
creased if concealment of allocation present (log RR = 0.52; 95%
CI 0.28 to 0.77 P < 0.001)).
Figure 6. Funnel plot of comparison: 8 Gastric ulcer recurrence with H. pylori eradication vs. no treatment
(after initial ulcer healing), outcome: 8.1 Proportion recurred.
H. pylori eradication therapy versus no treatment in
preventing the recurrence of peptic ulcer (after initial ulcer
had been healed)
One RCT (Arkkila 2005) reported a dichotomous peptic ulcer re-
currence outcome evaluating 103 participants at one year. Overall
8% of peptic ulcers recurred in the H. pylori eradication group
compared with 33% in the no treatment group. There was a sta-
tistically significant benefit of H. pylori eradication therapy com-
pared to no treatment in the prevention of peptic ulcer recurrence
(RR 0.23; 95% CI 0.09 to 0.59; Analysis 9.1) (NNTB = 4; 95%
CI 2 to 17).
Relief of symptoms from peptic ulcer
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H. pylori eradication therapy plus ulcer-healing drug versus
ulcer healing drug alone
Two RCTs (Higuchi 2003; Suarez 1999) reported a dichotomous
relief of symptoms from peptic ulcer evaluating 180 participants,
between four and six weeks. Overall 49% of symptoms resolved
in the H. pylori eradication group compared to 32% with ulcer
healing drug alone.Therewas statistically significant heterogeneity
between trial results (heterogeneity test (1 degree of freedom) Chi
2 statistic = 5.07, P = 0.02) and a random-effects model was used.
Therewas no statistically significant benefit ofH. pylori eradication
therapy compared to ulcer-healing drug in the relief of symptoms
from peptic ulcer (relative risk of symptoms persisting with H.
pylori eradication therapy compared to ulcer-healing drug (RR
0.86; 95% CI 0.42 to 1.74; Analysis 10.1).
H. pylori eradication therapy versus no treatment in the
relief of symptoms from peptic ulcer
Two RCTs (Lam 1997; Pounder 1997) reported a dichotomous
relief of symptoms from peptic ulcer evaluating 188 participants
at four weeks. Overall 21% of symptoms resolved in the H. pylori
eradication group compared to 42%with no treatment. There was
statistically significant heterogeneity between trial results (hetero-
geneity test (1 degree of freedom) Chi2 statistic = 4.19, P = 0.04)
and a random-effects model was used. There was no statistically
significant benefit of H. pylori eradication therapy compared to no
treatment in the relief of symptoms from peptic ulcer (relative risk
of symptoms persisting with H. pylori eradication therapy com-
pared to no treatment (RR 1.27; 95% CI 0.83 to 1.93; Analysis
10.2).
Side effect profile
Total number of adverse events
Forty-three trials (Arkkila 2005; Asaka 2001; Avsar 1996; Axon
1997; Bardhan 1997; Bayerdorffer 1992; Bayerdorffer 1995;
Bayerdorffer 1996; Befrits 2004; Bianchi Porro 1996; Carpintero
1997; Chen 1995; Fukuda 1995a; Fukuda 1995b; Graham 1991;
Graham 1998; Harford 1996; Hentschel 1993; Higuchi 2003;
Hosking 1992; Kato 1996; Lam 1997; Lazzaroni 1997; Lin 1994;
Logan 1995;Malfertheiner 1999;Mantzaris 1993;Meining 1998;
O’Morain 1996; Parente 1996; Pinero 1995; Pounder 1997;
Rauws 1990; Schwartz 1998; Shirotani 1996; Sobhani 1995;
Spinzi 1994; Suarez 1999; Sung 1995; Tomita 2002; Tulassay
2008; Wang 1996; Wong 1999) reported overall numbers of ad-
verse events as a dichotomous outcome in 6093 participants. In
total 22% of participants in the H. pylori eradication group expe-
rienced side-effects of therapy compared with 8% in the compari-
son regimen group. There was statistically significant heterogene-
ity between trial results (heterogeneity test (40 degrees of freedom)
Chi2 statistic = 80.47, P = 0.0002) and a random-effects model
was used. There was a statistically significant higher number of
adverse events with H. pylori eradication therapy over comparison
regimens (relative risk of adverse events with H. pylori eradication
therapy compared to comparison regimen (RR 2.30; 95%CI 1.77
to 2.99; Analysis 11.1) (NNTH = 10; 95% CI 8 to 14).
Diarrhoea
Thirty trials (Arkkila 2005; Asaka 2001; Bardhan 1997;
Bayerdorffer 1995; Bayerdorffer 1996; Bianchi Porro 1996;
Carpintero 1997; Chen 1995; Graham 1991; Graham 1998;
Harford 1996; Hentschel 1993; Kato 1996; Lam 1997; Lazzaroni
1997; Lin 1994; Logan 1995;Malfertheiner 1999;Meining 1998;
O’Morain 1996; Parente 1996; Pounder 1997; Rauws 1990;
Shirotani 1996; Sobhani 1995; Sung 1995; Tulassay 2008; Van
Zanten 1999; Wang 1996; Wong 1999) reported occurrence of
diarrhoea as a dichotomous outcome in 4590 participants. Over-
all 8% of participants in the H. pylori eradication group reported
diarrhoea compared with 2% in the comparison regimen group.
There was no statistically significant heterogeneity between trial
results (heterogeneity test (29 degrees of freedom) Chi2 statistic =
18.13, P = 0.94). There was a statistically significant higher num-
ber of participants reporting diarrhoea with H. pylori eradication
therapy over comparison regimens (relative risk of diarrhoea with
H. pylori eradication therapy compared to comparison regimen
(RR 2.86; 95% CI 2.11 to 3.88; Analysis 11.2) (NNTH = 24;
95% CI 17 to 37).
Nausea and/or vomiting
Fifteen trials (Bayerdorffer 1995; Bayerdorffer 1996; Carpintero
1997; Chen 1995; Graham 1991; Graham 1998; Lazzaroni 1997;
Lin 1994; Mantzaris 1993; Rauws 1990; Shirotani 1996; Suarez
1999; Sung 1995; Van Zanten 1999;Wang 1996) reported occur-
rence of nausea or vomiting, or both as a dichotomous outcome in
1533 participants.Overall 5%of participants in theH. pylori erad-
ication group reported nausea and/or vomiting compared with
0.5% in the comparison regimen group. There was no statistically
significant heterogeneity between trial results (heterogeneity test
(14 degrees of freedom) Chi2 statistic = 3.72, P = 1). There was
a statistically significant higher number of participants reporting
nausea and/or vomiting with H. pylori eradication therapy over
comparison regimens (relative risk of nausea and/or vomiting with
H. pylori eradication therapy compared to comparison regimen
(RR 3.76; 95% CI 1.91 to 7.37; Analysis 11.3) (NNTH = 25;
95% CI 17 to 50).
Skin rash
Eighteen trials (Arkkila 2005; Bayerdorffer 1996; Bianchi Porro
1996; Carpintero 1997; Chen 1995; Harford 1996; Hentschel
1993; Higuchi 2003; Kato 1996; Lam 1997; Logan 1995;
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Malfertheiner 1999; Meining 1998; Pounder 1997; Rauws 1990;
Suarez 1999; Tomita 2002; Wang 1996) reported occurrence of
skin rash as a dichotomous outcome in 2385 participants. Overall
2% of participants in theH. pylori eradication group reported skin
rash compared with 1% in the comparison regimen group. There
was no statistically significant heterogeneity between trial results
(heterogeneity test (17 degrees of freedom) Chi2 statistic = 10.60,
P = 0.88). There was no statistically significant higher number of
participants reporting skin rash with H. pylori eradication therapy
over comparison regimens (relative risk of skin rash with H. pylori
eradication therapy compared to comparison regimen (RR 1.36;
95% CI 0.78 to 2.37; Analysis 11.4).
Headache
Fourteen trials (Bardhan 1997; Bayerdorffer 1992; Bayerdorffer
1995; Bayerdorffer 1996; Carpintero 1997; Chen 1995; Graham
1998; Harford 1996; Logan 1995; Pinero 1995; Pounder 1997;
Sobhani 1995; Tulassay 2008; Van Zanten 1999) reported occur-
rence of headache as a dichotomous outcome in 2292 participants.
Overall 3% of participants in the H. pylori eradication group re-
ported headache compared with 3% in the comparison regimen
group. There was no statistically significant heterogeneity between
trial results (heterogeneity test (13 degrees of freedom) Chi2 statis-
tic = 7.27, P = 0.89). There was no statistically significant higher
number of participants reporting headache with H. pylori eradica-
tion therapy over comparison regimens (relative risk of headache
with H. pylori eradication therapy compared to comparison regi-
men (RR 1.11; 95% CI 0.70 to 1.75; Analysis 11.5).
Epigastric pain
Eleven trials (Bayerdorffer 1995; Bayerdorffer 1996; Bianchi Porro
1996; Carpintero 1997; Chen 1995; Logan 1995; Pounder 1997;
Sobhani 1995; Sung 1995; Van Zanten 1999; Wong 1999) re-
ported occurrence of epigastric pain as a dichotomous outcome
in 1491 participants. Overall 5% of participants in the H. pylori
eradication group reported epigastric pain compared with 0.6%
in the comparison regimen group. There was no statistically sig-
nificant heterogeneity between trial results (heterogeneity test (10
degrees of freedom) Chi2 statistic = 4.94, P = 0.9). There was
a statistically significant higher number of participants reporting
epigastric pain with H. pylori eradication therapy over comparison
regimens (relative risk of epigastric pain with H. pylori eradication
therapy compared to comparison regimen (RR 4.09; 95%CI 1.90
to 8.82; Analysis 11.6) (NNTH = 25; 95% CI 20 to 50).
Altered taste
Thirteen trials (Arkkila 2005; Asaka 2001; Bayerdorffer 1996;
Carpintero 1997; Fukuda 1995b; Logan 1995; Malfertheiner
1999; Mantzaris 1993; O’Morain 1996; Pinero 1995; Pounder
1997; Tulassay 2008; VanZanten 1999) reported occurrence of al-
tered taste as a dichotomous outcome in2299 participants.Overall
7% of participants in the H. pylori eradication group reported al-
tered taste compared with 0.4% in the comparison regimen group.
There was no statistically significant heterogeneity between trial
results (heterogeneity test (12 degrees of freedom) Chi2 statistic =
6.16, P = 0.91). There was a statistically significant higher num-
ber of participants reporting altered taste withH. pylori eradication
therapy over comparison regimens (relative risk of altered taste
with H. pylori eradication therapy compared to comparison regi-
men (RR 8.85; 95% CI 4.38 to 17.90; Analysis 11.7) (NNTH =
15; 95% CI 10 to 30).
Stomatitis
Eight trials (Arkkila 2005; Bayerdorffer 1996; Bianchi Porro 1996;
Carpintero 1997; Lazzaroni 1997; Shirotani 1996; Sobhani 1995;
Suarez 1999) reported occurrence of stomatitis as a dichotomous
outcome in 838 participants. Overall 2.5% of participants in the
H. pylori eradication group reported stomatitis compared to 0.3%
in the comparison regimen group. There was no statistically signif-
icant heterogeneity between trial results (heterogeneity test (seven
degrees of freedom) Chi2 statistic = 1.24, P = 0.99). There was
no statistically significant higher number of participants reporting
stomatitis with H. pylori eradication therapy over comparison reg-
imens (relative risk of stomatitis with H. pylori eradication therapy
compared to comparison regimen (RR 2.65; 95%CI 0.94 to 7.48;
Analysis 11.8).
21Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Additional Helicobacter pylori eradication therapy for prevention of recurrence in people with Helicobacter-positive peptic ulcer
Patient or population: prevent ion of recurrence in people with Helicobacter pylori-posit ive pept ic ulcer
Settings:
Intervention: Addit ional Helicobacter pylori eradicat ion therapy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Control Additional Helicobacter py-
lori eradication therapy
Proportion of people with duodenal ulcer with recurrence after maintenance therapy
H. pylori eradicat ion therapy
versus ulcer healing drug
alone
162 per 1000 119 per 1000
(68 to 203)
RR 0.73
(0.42 to 1.25)
319
(4 studies)
⊕©©©
very low1,2,3
H. pylori eradicat ion therapy
versus no act ive treatment
644 per 1000 129 per 1000
(97 to 167)
RR 0.2
(0.15 to 0.26)
2509
(27 studies)
⊕©©©
very low1,4,5
Proportion of people with gastric ulcer with recurrence after maintenance therapy
H. pylori eradicat ion therapy
versus no act ive treatment
524 per 1000 163 per 1000
(115 to 236)
RR 0.31
(0.22 to 0.45)
1476
(12 studies)
⊕©©©
very low1,4,5
Proportion of people with peptic ulcer (gastric or duodenal ulcer) with recurrence after maintenance therapy
H. pylori eradicat ion therapy
versus no act ive treatment
333 per 1000 77 per 1000
(30 to 197)
RR 0.23
(0.09 to 0.59)
103
(1 study)
⊕⊕©©
low1,2
None of the trials reported proport ion of people with recurrent gastric ulcer or pept ic ulcers during maintenance therapy between H.pylori eradicat ion therapy and ulcer-healing
drug therapy.
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* The basis for the assumed risk is the control group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 The risk of bias in trial(s) was high.
2 The sample size was small.
3 The conf idence intervals were wide.
4 There was moderate to signif icant heterogeneity as measured by I2 (Higgins 2003).
5 Possible small study ef fect/ publicat ion bias as suggested by funnel plot and tests for funnel plot asymmetry (Begg 1994;
Egger 1997).
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D I S C U S S I O N
Summary of main results
The most important finding of this review concerns the ulcer re-
currence rate of people with duodenal or gastric ulcer treated with
H. pylori eradication therapy compared to those given a short-
term course of ulcer-healing drug. There was a significant relative
risk reduction of 80% in the recurrence of duodenal ulcer, and
a slightly smaller but still significant risk ratio reduction of 69%
for gastric ulcer. The difference in results between duodenal and
gastric ulcer probably reflects the lower control relapse rate seen
in the latter disease. In addition, one week of H. pylori eradication
therapy appears to be at least as effective as maintenance therapy
with ulcer-healing drug in the recurrence of duodenal ulcer. This
review also finds that H. pylori eradication therapy has a small
benefit over ulcer-healing drug, and a larger benefit over no treat-
ment or placebo in the healing of duodenal ulcer. This does not
appear to be the case in the healing of gastric ulcer, where our
results show a slight increase in healing rates with ulcer-healing
drug alone. OverallH. pylori eradication rate in all trials was 68%.
Finally, there appears to be no significant improvement in relief of
symptoms of peptic ulcer disease with H. pylori eradication ther-
apy over comparison regimen, although the number of trials that
report this outcome is small. There are also no studies that have
evaluated symptoms beyond six weeks, and it is the long-term
effect of H. pylori eradication on peptic ulcer disease symptoms
that is important. These advantages are offset by an increased inci-
dence of short-term side effects. People receiving eradication ther-
apy report a higher incidence of side effects, with a greater than
two-fold increase in the risk of adverse events in people assigned
to comparison regimen rather than H. pylori eradication therapy.
Although these unwanted effects are only short-term they may be
significant (Moayyedi 2000).
Overall completeness and applicability of
evidence
Further trials comparingH. pylori eradication therapywith placebo
in the healing of gastric ulcer disease are required. In addition,
more trials reporting the effect of eradication therapy on symptoms
arising from peptic ulcer are required.
Quality of the evidence
Only a small proportion of all trials identified were of high qual-
ity, in terms of their reporting of the methods used to generate
the randomisation sequence and conceal treatment allocation. In
addition, a significant number did not report losses to follow-up
completely and could not be judged to be free from selective re-
porting. Details of these issues are provided in the ’Summary of
findings’ tables.
Potential biases in the review process
We have explored reasons for heterogeneity in the results using
metaregression. These results need to be interpreted with caution
as metaregression evaluates the average of patient characteristics
within each trial and is open to giving spurious results due to the
ecological fallacy (Lau 1998). Nevertheless the finding that effects
size was reduced in trials with adequate concealment of allocation
in the long term gastric ulcer recurrence trials, and effect size in-
creased with absence of blinding in short term gastric ulcer healing
trials, is consistent with previous reports of the general systematic
review literature (Moher 1999). The reduction of effect size with
intention-to-treat analysis in the long-term duodenal and gastric
ulcer recurrence trials is also consistent with this literature (Moher
1999) and the increase in effect size with increasing eradication
rate is biologically plausible.
Agreements and disagreements with other
studies or reviews
These findings support the recommendations of the EuropeanHe-
licobacter pylori Study Group (EHPSG) and the American Gas-
troenterological Association, both of which recommend a recog-
nised course ofH. pylori eradication therapy for the treatment ofH.
pylori-positive peptic ulcer disease (Howden 1998; Malfertheiner
2002b). This approach is also advocated from a health economic
perspective frommodels (Briggs 1996; Imperiale 1995) and also a
randomised controlled trial (Sonnenberg 1998), all of which show
a reduced use of ulcer-related health care resources compared to
conventional ulcer-healing drug therapy in subsequent follow-up.
Two systematic reviews have previously been conducted in this
area (Leodolter 2001; Moore 1994). Both these reviews reported
a greater benefit fromH. pylori eradication therapy in peptic ul-
cer disease than our review. In the earlier of these studies (Moore
1994), ulcer-healing rates of 90%to95%withH. pylori eradication
therapy were reported, compared to 75% to 85% in our review,
and ulcer-recurrence rates of less than 10%, compared to 12% to
15%. The more recent (Leodolter 2001) quoted healing rates of
87% to 93% and recurrence rates of 2% to 3%. This could be
accounted for by our use of intention-to-treat data. We assumed
all participants lost to follow-up in the trials were treatment fail-
ures, whereas the authors of the two previous studies only used
intention-to-treat data where reported.
The study by Moore was performed in 1994 and there has been
considerable information published in the interim period. In ad-
dition, the study author did not perform a separate analysis for
duodenal and gastric ulcers, but amalgamated results into an over-
all healing and recurrence rate for peptic ulcers. The later meta-
analysis, Leodolter 2001 has several differences from our review.
Firstly, it was designed to reveal the efficacy of eradication therapy
in healing and preventing recurrence of duodenal ulcer compared
to gastric ulcer. This means that articles were only eligible for in-
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clusion if they contained data for both duodenal and gastric ulcer
healing or recurrence, reported separately. Secondly, in order to
’limit’ the number of studies eligible for inclusion in the healing
analysis only trials that used PPI-based eradication regimens were
used. Finally, there were several non-randomised or uncontrolled
studies, or both included in the analysis. Neither of these two pre-
vious reviews reported data for symptom relief or adverse events.
We have addressed all these issues in our review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Adding a one to two-week course of H. pylori eradication therapy
is an effective treatment for people with H. pylori-positive duo-
denal ulcer when compared to ulcer-healing drugs alone and no
treatment. H. pylori eradication therapy is also effective in pre-
venting recurrence of duodenal and gastric ulcer compared to no
treatment. There is currently no evidence thatH. pylori eradication
therapy is an effective treatment in people with gastric ulcer or that
it is effective in preventing recurrence of duodenal ulcer compared
to ulcer-healing drug. However, confidence intervals were wide
and significant benefits or harms of H. pylori eradication therapy
in acute ulcer healing of gastric ulcers compared to no treatment
and in preventing recurrence of duodenal ulcers compared to ulcer
healing drugs cannot be ruled out.
Implications for research
This review has identified some directions for further research.
In the future, papers should state the method of randomisation,
allocation of concealment, and masking more clearly. More trials
are needed to evaluate H. pylori eradication therapy in the healing
of gastric ulcer disease, particularly comparing antibiotic therapy
with placebo. Finally, there has been little data on symptom relief
and quality of life changes and this should be addressed.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Arkkila 2005
Methods Multi-centre RCT
Double-blinded
Participants Finland
115 people with peptic ulcer
Interventions Bi quadruple therapy (2 weeks colloidal bismuth subcitrate 120 mg qds, lansoprazole
30 mg bd, tetracycline 500 mg qds, and metronidazole 400 mg qds) PPI triple therapy
(2 weeks lansoprazole 30 mg bd, amoxicillin 500 mg qds, and clarithromycin 500 mg
tds) PPI dual therapy (lansoprazole 30 mg bd and amoxicillin 500 mg qds) versus PPI
(lansoprazole 30 mg bd for 2 weeks, then 30 mg od for 2 weeks)
Outcomes Ulcer healing
Ulcer recurrence
H. pylori eradication rates
Notes Eradication rates:
Bi quadruple therapy 89%
PPI triple therapy 100%
PPI dual therapy 80%
PPI 0%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Treatment groups were determined by a list of
random numbers generated by computer
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk Endoscopists were blinded for the treatment
Incomplete outcome data (attrition bias)
All outcomes
High risk There were post-randomisation drop-outs
Selective reporting (reporting bias) High risk Collected serology for H. pylori status but did not
record these data
Other bias High risk Participants in placebo arm had H. pylori eradica-
tion at 8 weeks so 12 month follow-up not ran-
domised
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Asaka 2001
Methods Multi-centre RCT
Double-blinded
Participants Japan
536 people with gastric or duodenal ulcer
Interventions PPI triple therapy (5 weeks (DU)/7 weeks (GU) lansoprazole 30 mg bd, 1 week amoxi-
cillin 750 mg bd and clarithromycin 200 mg/400 mg bd) versus PPI (5 weeks (DU)/7
weeks (GU) lansoprazole 30 mg bd)
Outcomes Ulcer healing
H. pylori eradication rates
Notes Eradication rates:
PPI triple therapy group 76.9%
PPI group 1.89%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Incomplete outcome data (attrition bias)
All outcomes
High risk There were post-randomisation drop-outs
Selective reporting (reporting bias) Low risk Collected data was reported
Other bias Low risk There was no other bias
Avsar 1996
Methods Single-centre RCT
Single-blinded
Participants Turkey
45 people with duodenal ulcer
Interventions Bi triple therapy (4 weeks colloidal bismuth subcitrate 120 mg qds, 2 weeks tetracycline
250 mg qds and metronidazole 250 mg tds) versus PPI (8 weeks omeprazole 40 mg od)
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Avsar 1996 (Continued)
Outcomes Ulcer healing
Ulcer recurrence at 1 year
H. pylori eradication rates
Notes Eradication rates:
Bi triple therapy group 78.3%
PPI group 36.4%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Endoscopies were performed by one of the au-
thors, who was blinded to the clinical data, bacte-
riological findings and treatment regimen”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 20/45 (44%) lost to follow up
Selective reporting (reporting bias) High risk Symptom data collected but not reported in suffi-
cient detail
Other bias Low risk There was no other bias
Axon 1997
Methods Multi-centre RCT
Double-blinded
Participants UK and Republic of Ireland
129 people with gastric ulcer
Interventions PPI dual therapy (8 weeks omeprazole 40mg od and 2 weeks amoxicillin 750 mg bd)
versus PPI (8 weeks omeprazole 40 mg od)
Outcomes Ulcer healing
Ulcer recurrence at 1 year
H. pylori eradication rates
Notes Eradication rates:
PPI dual therapy group 48.3%
PPI group 4.8%
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Axon 1997 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “randomisation... From a computer generated
randomisation list”
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk “double blind, double dummy design”
Incomplete outcome data (attrition bias)
All outcomes
High risk There were post-randomisation drop-outs
Selective reporting (reporting bias) Low risk Collected data was reported
Other bias Low risk There was no other bias
Bardhan 1997
Methods Multi-centre RCT
Double-blinded
Participants Multi-national
232 people with duodenal ulcer
Interventions RBC dual therapy (2 weeks RBC 400 mg/800 mg bd and clarithromycin 250 mg qds,
then 2 weeks RBC 400 mg bd) versus RBC (4 weeks RBC 400 mg bd)
Outcomes Ulcer healing
Ulcer recurrence at 28 weeks
H. pylori eradication rates
Notes Eradication rates:
RBC dual therapy 76.6%
RBC 1.4%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
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Bardhan 1997 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk “double blind,double dummy”
Incomplete outcome data (attrition bias)
All outcomes
High risk There were post-randomisation drop-outs
Selective reporting (reporting bias) Low risk Collected data was reported
Other bias Low risk There was no other bias
Bayerdorffer 1992
Methods Multi-centre RCT
Single-blinded
Participants Germany
58 people with duodenal ulcer
Interventions PPI dual therapy (10 days omeprazole 40 mg bd and amoxicillin 1 g bd, then 4 1/2
weeks omeprazole 20 mg od) versus PPI (10 days omeprazole 40 mg bd then 4 1/2 weeks
omeprazole 20 mg od)
Outcomes Ulcer healing
H. pylori eradication rates
Notes Eradication rates:
PPI dual therapy 75.9%
PPI 0%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk “investigator blinded clinical trial”
Incomplete outcome data (attrition bias)
All outcomes
High risk There were post-randomisation drop-outs
Selective reporting (reporting bias) High risk Endoscopy performed if symptoms recurred but
this data not given
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Bayerdorffer 1992 (Continued)
Other bias Low risk There was no other bias
Bayerdorffer 1995
Methods Multi-centre RCT
Double-blinded
Participants Germany
264 people with duodenal ulcer
Interventions PPI dual therapy (2 weeks omeprazole 40 mg tds and amoxicillin 750 mg tds, then 4
weeks omeprazole 20 mg od) versus PPI (2 weeks omeprazole 40 mg tds then 4 weeks
omeprazole 20 mg od)
Outcomes Ulcer healing
Ulcer recurrence at 1 year
H. pylori eradication rates
Notes Eradication rates:
PPI dual therapy 88.9%
PPI 0%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk “double blind” “placebo treatment”
Incomplete outcome data (attrition bias)
All outcomes
High risk There were post-randomisation drop-outs
Selective reporting (reporting bias) High risk Highlighted differences in pretreatment with
omeprazole but it is hard to believe that this was
the only subgroup analysed
Other bias Low risk There was no other bias
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Bayerdorffer 1996
Methods Multi-centre RCT
Single-blinded
Participants Germany
130 people with gastric ulcer
Interventions Bi triple therapy (8 weeks bismuth subsalicylate 600 mg tds, 10 days amoxicillin 500
mg bd and tinidazole 1 g bd) versus PPI (8 weeks omeprazole 20 mg od)
Outcomes Ulcer healing
Ulcer recurrence at 18 months
H. pylori eradication rates
Notes Eradication rates:
Bi triple therapy 66.1%
PPI 7.7%
If ulcer not healed at 8 weeks Bi/PPI continued for a further 4 weeks
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Low risk “Randomisation was carried out by a central study
secretariat”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “investigator blinded”
Incomplete outcome data (attrition bias)
All outcomes
High risk There were post-randomisation drop-outs
Selective reporting (reporting bias) Low risk Collected data was reported
Other bias Low risk There was no other bias
Befrits 2004
Methods Multi-centre RCT
Double-blinded
Participants Sweden
103 people with gastric ulcer
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Befrits 2004 (Continued)
Interventions PPI triple therapy (1 week omeprazole 20 mg bd, metronidazole 400 mg bd, clar-
ithromycin 250 mg bd) versus PPI (1 week omeprazole 20 mg bd then 3 weeks 20 mg
od)
Outcomes Ulcer healing
Ulcer recurrence at 5 years
H. pylori eradication rates
Notes Eradication rates:
PPI triple therapy 64%
PPI 2%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk “double blind? Using placebo of the same size and
appearance as conventional metronidazole and
clarithromycin tablets”
Incomplete outcome data (attrition bias)
All outcomes
High risk There were post-randomisation drop-outs
Selective reporting (reporting bias) High risk Symptom data collected but not reported in suf-
ficient detail
Other bias Low risk There was no other bias
Bianchi Porro 1993
Methods Single-centre RCT
Double-blinded
Participants Italy
183 people with duodenal ulcer
Interventions Bi triple therapy (4 weeks colloidal bismuth subcitrate 120 mg qds, 1 week amoxicillin
1 g tds and tinidazole 500 mg bd) versus sucralfate (4 weeks 1 g qds)
Outcomes Ulcer healing
Ulcer recurrence at 1 year
H. pylori eradication rates
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Bianchi Porro 1993 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “allocated, according to a randomised list”
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk This information was not available
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reported according to H. pylori status for 12
month data rather than randomised groups
Selective reporting (reporting bias) Low risk Collected data was reported
Other bias High risk Reported data according to H. pylori status rather
than ITT
Bianchi Porro 1996
Methods Single-centre RCT
Unblinded
Participants Italy
32 people with duodenal ulcer
Interventions PPI triple therapy (4 weeks omeprazole 20 mg od, 2 weeks metronidazole 250 mg qds
and amoxicillin 1 g tds) versus PPI (4 weeks omeprazole 20 mg od)
Outcomes Ulcer healing
Ulcer recurrence at one year
H. pylori eradication rates
Notes If the ulcer did not heal, participants crossed over to other therapy, therefore we were
unable to extract eradication rates
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
40Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bianchi Porro 1996 (Continued)
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding was not performed
Incomplete outcome data (attrition bias)
All outcomes
High risk There were post-randomisation drop-outs
Selective reporting (reporting bias) Low risk Collected data was reported
Other bias Low risk There was no other bias
Carpintero 1997
Methods Single-centre RCT
Unblinded
Participants Spain
122 people with duodenal ulcer
Interventions Bi triple therapy (6 weeks colloidal bismuth subcitrate 120 mg qds, 12 days amoxicillin
500 mg tds and metronidazole 500 mg bd) or H2RA triple therapy (6 weeks ranitidine
300 mg qds, 12 days amoxicillin 500 mg tds and metronidazole 500 mg bd) versus
H2RA (6 weeks ranitidine 300 mg qds)
Outcomes Ulcer healing
Ulcer recurrence at 18 months
H. pylori eradication rates
Notes Eradication rates:
Bi triple therapy 86.8%
H2RA triple therapy 25%
H2RA 0%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “treatment assignments were determined by a list of
random numbers generated by computer”
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding was not performed
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Carpintero 1997 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Data only on group A 39/44, Group B 38/40 and
group C 34/38 at 12 months
Selective reporting (reporting bias) Low risk Collected data was reported
Other bias Low risk There was no other bias
Chen 1995
Methods Single-centre RCT
Single-blinded
Participants Taiwan
62 people with duodenal ulcer
Interventions Bi triple therapy (1 or 2 weeks colloidal bismuth subcitrate 120 mg qds, amoxicillin 500
mg tds and metronidazole 500 mg tds) versus no treatment
Outcomes Ulcer recurrence at 1 year
H. pylori eradication rates
Notes Eradication rates:
Bi triple therapy 93.9%
No treatment 0%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding was not performed
Incomplete outcome data (attrition bias)
All outcomes
High risk There were post-randomisation drop-outs
Selective reporting (reporting bias) High risk Dyspepsia symptoms obtained but not reported
Other bias Low risk There was no other bias
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Feng 2005
Methods Single-centre RCT
Double-blinded
Participants China
75 people with peptic ulcer
Interventions PPI triple therapy (10 days lansoprazole 30 mg qds, clarithromycin 250 mg bd, amox-
icillin 500 mg bd) versus ’killing’ quadruple therapy (10 days lansoprazole 30 mg qds,
clarithromycin 250 mg bd, amoxicillin 500 mg bd and 4 weeks H. pylori ’killing’ capsule
6 bd) versus placebo
Outcomes Ulcer healing at 4 weeks
Ulcer recurrence at 5 years
H. pylori eradication rates
Notes Eradication rates:
PPI triple therapy 94%
PPI 0%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk ”double blind“, The medicine, starch or placebo
(gastropine)was packed in gelatin capsules of sim-
ilar appearance. The investigators did not know
what medicines were given to patients, and the
patients did not know what medicines they had
taken”
Incomplete outcome data (attrition bias)
All outcomes
High risk Data from 5 participants not reported on at one
year
Selective reporting (reporting bias) High risk Dyspepsia symptoms data obtained but not re-
ported (only that upper abdominal pain was sig-
nificantly less (P < 0.05) in group B)
Other bias Low risk There was no other bias
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Figueroa 1996
Methods Single-centre RCT
Unblinded
Participants Chile
113 people with duodenal ulcer
Interventions Bi quadruple therapy (4 weeks omeprazole 20mg qds, bismuth subsalicylate 524mg qds,
amoxicillin 500 mg tds and metronidazole 250 mg tds) versus PPI (4 weeks omeprazole
20nmg od)
Outcomes Ulcer healing
Ulcer recurrence at 1 year
H. pylori eradication rates
Notes Eradication rates:
Bi quadruple therapy 82.5%
PPI 0%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk “single blind”
Incomplete outcome data (attrition bias)
All outcomes
High risk There were post-randomisation drop-outs
Selective reporting (reporting bias) Low risk Collected data was reported
Other bias Low risk There was no other bias
Fukuda 1995a
Methods Single-centre RCT
Unblinded
Participants Japan
65 people with gastric ulcer
Interventions PPI dual therapy (8 weeks lansoprazole 30 mg od and 2 weeks clarithromycin 200 mg
tds) versus PPI (8 weeks omeprazole 20 mg od or lansoprazole 30 mg od)
44Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Fukuda 1995a (Continued)
Outcomes Ulcer healing
H. pylori eradication rates
Notes Eradication rates:
PPI dual therapy 62.5%
PPI 24.2%
All participants received 4 weeks’ ranitidine 150 mg od after initial therapy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding was not performed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk This information was not available
Selective reporting (reporting bias) Unclear risk This information was not available
Other bias Low risk There was no other bias
Fukuda 1995b
Methods Single-centre RCT
Single-blinded
Participants Japan
86 people with gastric ulcer
Interventions PPI dual therapy (8 weeks lansoprazole 30 mg qds and 2 weeks clarithromycin 200 mg
tds/amoxicillin 500 mg tds) versus PPI (8 weeks omeprazole 20 mg qds or lansoprazole
30 mg qds)
Outcomes Ulcer healing
Ulcer recurrence at 40 weeks
H. pylori eradication rates
Notes Eradication rates:
PPI dual therapy 48.6%
PPI 12.2%
All participants received 4 weeks ranitidine 150 mg od after initial therapy
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Fukuda 1995b (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk “endoscopy was performed at 3month intervals by
a gastroenterologist who was kept uninformed of
the details of the patients’ past medical histories”
Incomplete outcome data (attrition bias)
All outcomes
High risk Data from 2 participants missing
Selective reporting (reporting bias) Low risk Collected data was reported
Other bias Low risk There was no other bias
Furuta 1995
Methods Single-centre RCT
Unblinded
Participants Japan
67 people with gastric or duodenal ulcer
Interventions PPI dual therapy (6 weeks lansoprazole 30 mg qds and 2 weeks amoxicillin 1-2 g qds)
versus PPI (6 weeks lansoprazole 30 mg qds)
Outcomes Ulcer healing
H. pylori eradication rates
Notes Eradication rates:
PPI dual therapy 62.5%
PPI 0%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
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Furuta 1995 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
High risk There was no blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Numbers not given at endof follow-up just percentages
Selective reporting (reporting bias) Low risk Collected data was reported
Other bias Low risk There was no other bias
Graham 1991
Methods Single-centre RCT
Single-blinded
Participants USA
105 people with duodenal ulcer
Interventions Bi triple therapy (2 weeks bismuth subsalicylate 300 mg qds/150 mg tds + 300 mg
nocte, tetracycline 500 mg qds and metronidazole 250 mg tds) versus H2RA (16 weeks
ranitidine 300 mg od)
Outcomes Ulcer healing
H. pylori eradication rates
Notes Eradication rates:
Bi triple therapy 82.7%
H2RA 0%
All participants received 16 weeks H2RA
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk “results were not shared with the endoscopist”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Percentages rather than numbers given for follow-
up data (6 lost to follow up in the eradication
group)
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Graham 1991 (Continued)
Selective reporting (reporting bias) High risk Symptom data collected but not reported
Other bias Low risk There was no other bias
Graham 1992
Methods Single-centre RCT
Single-blinded
Participants USA
109 people with gastric or duodenal ulcer
Interventions Bi triple therapy
(2 weeks bismuth subsalicylate 300 mg qds/150 mg tds + 300 mg nocte, tetracycline
500 mg qds and metronidazole 250 mg tds) versus H2RA (16 weeks ranitidine 300 mg
od)
Outcomes Ulcer recurrence at 1 year
H. pylori eradication rates
Notes Eradication rates:
Bi triple therapy 88.7%
H2RA 0%
All participants received 16 weeks H2RA
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk “the endoscopist was blinded to the treatment sta-
tus of the patient”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 83/112 (74%) with ulcer healing agreed to enter
follow-up part of study
Selective reporting (reporting bias) High risk Symptom data collected but not reported
Other bias Low risk There was no other bias
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Graham 1998
Methods Multi-centre RCT
Double-blinded
Participants USA and Puerto Rico
153 people with duodenal ulcer
Interventions RBC dual therapy (4 weeks RBC 400 mg bd, 2 weeks amoxicillin 500 mg qds) versus
Bi (4 weeks RBC 400 mg bd) and placebo
Outcomes Ulcer healing
Ulcer recurrence at 6 months
H. pylori eradication rates
Notes Eradication rates:
RBC dual therapy 40%
RBC 0%
Placebo 0%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk “double blind” placebo
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 24-week data reported as percentage not absolute
numbers
Selective reporting (reporting bias) High risk 24-week data according to H. pylori status not
randomised groups
Other bias Low risk There was no other bias
Harford 1996
Methods Multi-centre RCT
Double-blinded
Participants USA
196 people with duodenal ulcer
Interventions PPI dual therapy (2 weeks lansoprazole 30 mg bd/tds and amoxicillin 1 g tds) versus PPI
(2 weeks lansoprazole 30 mg tds)
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Harford 1996 (Continued)
Outcomes Ulcer healing
H. pylori eradication rates
Notes Eradication rates:
PPI dual therapy 55.1%
PPI 0%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk “matching placebos were supplied tomaintain the
double-blind nature of the study”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Ulcer data missing on 50/262 (19%) subjects
Selective reporting (reporting bias) Low risk Collected data was reported
Other bias Low risk There was no other bias
Hentschel 1993
Methods Two centre RCT
Double-blinded
Participants Austria
104 people with duodenal ulcer
Interventions H2RA triple therapy (6 weeks ranitidine 300 mg od, 12 days amoxicillin 750 mg tds
and metronidazole 500 mg tds) versus H2RA (6 weeks ranitidine 300 mg od)
Outcomes Ulcer healing
Ulcer recurrence at 1 year
H. pylori eradication rates
Notes Eradication rates:
H2RA triple therapy 88.5%
H2RA 1.9%
If ulcer not healed at 6 weeks ranitidine continued for a further 4 weeks
Risk of bias
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Hentschel 1993 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk “identical appearing placebos”
Incomplete outcome data (attrition bias)
All outcomes
High risk 1/104 dropped out (from eradication group)
Selective reporting (reporting bias) High risk Histology taken but not reported
Other bias Low risk There was no other bias
Higuchi 2003
Methods Two-centre RCT
Single-blinded
Participants Japan
120 people with gastric ulcer
Interventions PPI triple therapy (1week lansoprazole 30mgodor rabeprazole 20mgodplus amoxicillin
1.5 g od and clarithromycin 800mgod) versus PPI (lansoprazole 30mg od or rabeprazole
20 mg od)
Outcomes Ulcer healing
Global symptoms cured
H. pylori eradication rates
Notes Eradication rates:
PPI triple therapy 83.6%
PPI 0%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “a table of random numbers was used to generate the
randomisation sequence”
Allocation concealment (selection bias) Low risk “using sealed opaque envelopes numbered sequen-
tially and containing the assignment”
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Higuchi 2003 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Patients and their physicians were aware of the treat-
ment assignment, but endoscopists and pathologists
were not”
Incomplete outcome data (attrition bias)
All outcomes
High risk 109/120 (91%) completed trial
Selective reporting (reporting bias) Low risk Collected data was reported
Other bias Low risk There was no other bias
Hosking 1992
Methods Single-centre RCT
Single-blinded
Participants Hong Kong
155 people with duodenal ulcer
Interventions Bi quadruple therapy (4weeks omeprazole 40mgqds, 1week colloidal bismuth subcitrate
120 mg qds, tetracycline 500 mg qds and metronidazole 400 mg qds) versus PPI (4
weeks omeprazole 40 mg qds)
Outcomes Ulcer healing
Ulcer recurrence at 1 year
H. pylori eradication rates
Notes Eradication rates:
Bi quadruple therapy 89.7%
PPI 3.9%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “randomised by instructions”
Allocation concealment (selection bias) Low risk “randomised in consecutively numbered sealed
opaque envelopes”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “staff performing the endoscopic and bacteriologic
assessments were unaware of the drugs the patient
had been taking”
Incomplete outcome data (attrition bias)
All outcomes
High risk There were post-randomisation drop-outs
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Hosking 1992 (Continued)
Selective reporting (reporting bias) Low risk Collected data was reported
Other bias Low risk There was no other bias
Kato 1996
Methods Single-centre RCT
Unblinded
Participants Japan
119 people with gastric or duodenal ulcer
Interventions PPI dual therapy (6 weeks (DU)/8 weeks (GU) lansoprazole 30 mg od and 2 weeks
amoxicillin 500 mg qds) versus PPI (6 weeks (DU)/8 weeks (GU) lansoprazole 30 mg
od)
Outcomes Ulcer healing
Ulcer recurrence at 1 year
H. pylori eradication rates
Notes Eradication rates:
PPI dual therapy 36.5%
PPI 1.8%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding was not performed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 99/119 (83%) completed 1 year follow up
Selective reporting (reporting bias) Low risk Collected data was reported
Other bias Low risk There was no other bias
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Katoh 1995
Methods Single-centre RCT
Unblinded
Participants Japan
133 people with gastric or duodenal ulcer
Interventions PPI dual therapy (6 weeks (DU)/8 weeks (GU) lansoprazole 30 mg od and 2 weeks
amoxicillin 500 mg qds) versus PPI (6 weeks (DU)/8 weeks (GU) lansoprazole 30mg
od)
Outcomes Ulcer healing
H. pylori eradication rates
Notes Eradication rates:
PPI dual therapy 38.8%
PPI 9.4%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding was not performed
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no post-randomisation drop-outs
Selective reporting (reporting bias) Low risk Collected data was reported
Other bias Low risk There was no other bias
Kepecki 1999
Methods Single-centre RCT
Unblinded
Participants Turkey
73 people with duodenal ulcer
Interventions PPI triple therapy (1 week omeprazole 20 mg bd, amoxicillin 1 g bd and metronidazole
500 mg tds, then 3 weeks omeprazole 20 mg od) versus PPI (1 week omeprazole 20 mg
bd then 3 weeks 20 mg od)
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Kepecki 1999 (Continued)
Outcomes Ulcer healing
Ulcer recurrence at 2 years
H. pylori eradication rates
Notes Eradication rates:
PPI triple therapy 82%
PPI 0%
PPI group received long-term famotidine 20 mg od
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding was not performed
Incomplete outcome data (attrition bias)
All outcomes
High risk There were post-randomisation drop-outs
Selective reporting (reporting bias) Low risk Collected data was reported
Other bias Low risk There was no other bias
Kim 2002
Methods Single-centre RCT
Single-blinded
Participants South Korea
53 people with duodenal ulcer
Interventions PPI triple therapy (1 week omeprazole 20 mg bd, amoxicillin 1 g bd and clarithromycin
500 mg bd) versus no treatment
Outcomes Ulcer recurrence at 30 months
H. pylori eradication rates
Notes Eradication rates:
PPI triple therapy 83.3%
No treatment 0%
Participants with ulcers not eradicated with triple therapy received Bi quadruple therapy
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Kim 2002 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “randomised?.using a computer generated list”
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk “two experienced endoscopists, who were blind to
the clinical data”
Incomplete outcome data (attrition bias)
All outcomes
High risk “no patient was lost to follow up”
Selective reporting (reporting bias) Low risk Collected data was reported
Other bias Low risk There was no other bias
Lam 1997
Methods Single-centre RCT
Double-blinded
Participants Hong Kong
97 people with duodenal ulcer
Interventions Clarithromycin monotherapy (2 weeks clarithromycin 250 mg qds) versus placebo
Outcomes Ulcer healing
Global symptoms cured
H. pylori eradication rates
Notes Eradication rates:
Clarithromycin monotherapy 70.8%
Placebo 10.2%
Clarithromycin participants also received amoxicillin and metronidazole
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
56Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lam 1997 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk “placebo capsules were identical in appearance
and taste”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 81/97 (83%) completed the trial
Selective reporting (reporting bias) Low risk Collected data was reported
Other bias Low risk There was no other bias
Lazzaroni 1997
Methods Single-centre RCT
Double-blinded
Participants Italy
59 people with gastric ulcer
Interventions PPI dual therapy (4 weeks omeprazole 20 mg bd and 2 weeks amoxicillin 1 g tds) versus
PPI (4 weeks omeprazole 20 mg bd)
Outcomes Ulcer healing
Ulcer recurrence at 1 year
H. pylori eradication rates
Notes Eradication rates:
PPI dual therapy 62.1%
PPI 6.7%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “allocated according to a computer generated ran-
domisation list”
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk “double blind” placebo
Incomplete outcome data (attrition bias)
All outcomes
Low risk 15/59 (25%) lost to follow up
Selective reporting (reporting bias) High risk Symptom data collected but not reported in suf-
ficient detail
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Lazzaroni 1997 (Continued)
Other bias Low risk There was no other bias
Lin 1994
Methods Single-centre RCT
Unblinded
Participants Taiwan
42 people with duodenal ulcer
Interventions Bi triple therapy (4weeks colloidal bismuth subcitrate 120mg qds, 1 weekmetronidazole
250 mg qds and amoxicillin 500 mg qds) versus H2RA (4 weeks famotidine 20 mg bd)
Outcomes Ulcer healing
Ulcer recurrence at 1 year
H. pylori eradication rates
Notes Eradication rates:
Bi triple therapy 100%
H2RA 4.8%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding was not performed
Incomplete outcome data (attrition bias)
All outcomes
High risk 3/42 (7%) lost to follow up at 12 months
Selective reporting (reporting bias) Low risk Collected data was reported
Other bias Low risk There was no other bias
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Logan 1995
Methods Multi-centre RCT
Double-blinded
Participants UK
148 people with duodenal ulcer
Interventions PPI dual therapy (4 weeks omeprazole 40 mg od and 2 weeks clarithromycin 500 mg
tds) versus PPI (4 weeks omeprazole 40 mg od)
Outcomes Ulcer healing
Ulcer recurrence at 1 year
H. pylori eradication rates
Notes Eradication rates:
PPI dual therapy 81.4%
PPI 1.3%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk “identically appearing placebo”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “17 clarithromycin treated patients lost to follow
up”
Selective reporting (reporting bias) High risk Symptom data not reported at one year
Other bias Low risk There was no other bias
Malfertheiner 1999
Methods Multi-centre RCT
Double-blinded
Participants Germany, Hungary and Poland
145 people with gastric ulcer
Interventions PPI triple therapy (1 week omeprazole 20 mg bd, amoxicillin 1 g bd and clarithromycin
500mgbdor 1week omeprazole 20mgbd,metronidazole 400mgbd and clarithromycin
250 mg bd) versus PPI (1 week omeprazole 20 mg bd)
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Malfertheiner 1999 (Continued)
Outcomes Ulcer healing
Ulcer recurrence at 6 months
H. pylori eradication rates
Notes Eradication rates:
PPI triple therapy 82.4%
PPI 4.2%
PPI given until ulcer healing in control arm
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk “identical tablets/capsules containing active drug
or placebo”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number lost to follow up at 6 months not stated
Selective reporting (reporting bias) Low risk Collected data was reported
Other bias Low risk There was no other bias
Mantzaris 1993
Methods Single-centre RCT
Single-blinded
Participants Greece
33 people with duodenal ulcer
Interventions Bi triple therapy (8 weeks colloidal bismuth subcitrate 120 mg qds, 2 weeks tetracycline
500 mg qds and metronidazole 500 mg tds) versus Bi (8 weeks colloidal bismuth subci-
trate 120 mg qds)
Outcomes Ulcer healing
Ulcer recurrence at 18 months
H. pylori eradication rates
Notes Eradication rates:
Bi triple therapy 58.8%
Bi 6.3%
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Mantzaris 1993 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Endoscopies were all performed by the same
physician who was unaware of the patient’s treat-
ment category”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3/12 inH. pylori eradication armwithdrew because
of side effects
Selective reporting (reporting bias) High risk Symptom data collected but not reported in suffi-
cient detail
Other bias Low risk There was no other bias
Meining 1998
Methods Multi-centre RCT
Double-blinded
Participants Germany
185 people with gastric ulcer
Interventions PPI dual therapy (2 weeks omeprazole 40 mg bd and amoxicillin 750 mg tds then 2
weeks omeprazole 20 mg od) versus PPI (2 weeks omeprazole 40 mg bd then 2 weeks
omeprazole 20 mg od)
Outcomes Ulcer healing
Ulcer recurrence at 3 months
H. pylori eradication rates
Notes Eradication rates:
PPI dual therapy 61%
PPI 5.9%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Each centre had its own randomisation list”
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Meining 1998 (Continued)
Allocation concealment (selection bias) Low risk “Randomisationwas carried out by a central study
secretariat”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “amoxicillin-placebo” “double-blind trial”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 23/185 (12%) missed follow up
Selective reporting (reporting bias) High risk Symptom data collected but not reported
Other bias Low risk There was no other bias
Mones 2001
Methods Multi-centre RCT
Double-blinded
Participants Spain
85 people with duodenal ulcer
Interventions PPI triple therapy (1 week omeprazole 20 mg bd, amoxicillin 1 g bd and clarithromycin
500 mg bd then 3 weeks omeprazole 20 mg od) versus PPI (1 week omeprazole 20 mg
bd then 3 weeks omeprazole 20 mg od)
Outcomes Ulcer healing
Ulcer recurrence at 1 year
H. pylori eradication rates
Notes Eradication rates:
PPI triple therapy 76.2%
PPI 0%
PPI participants given 1 year of ranitidine 150 mg od
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “using a computerized randomisation program”
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk “double blind” “antibiotic matching placebo”
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Mones 2001 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk This information was not available
Selective reporting (reporting bias) High risk Dyspepsia symptoms obtained but not reported
Other bias Low risk There was no other bias
O’Morain 1996
Methods Multi-centre RCT
Double-blinded
Participants Republic of Ireland, Germany and New Zealand
208 people with duodenal ulcer
Interventions PPI dual therapy (2 weeks omeprazole 40 mg od and clarithromycin 500 mg tds, then
2 weeks omeprazole 20 mg od) versus PPI (2 weeks omeprazole 40 mg od then 2 weeks
20 mg od)
Outcomes Ulcer healing
Ulcer recurrence at 6 months
H. pylori eradication rates
Notes Eradication rates:
PPI dual therapy 62.7%
PPI 0.9%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk “double-blind” “identically appearing placebo”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 33/208 (16%) did not have follow up endoscopy
Selective reporting (reporting bias) Low risk Collected data was reported
Other bias Low risk There was no other bias
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Parente 1996
Methods Single-centre RCT
Unblinded
Participants Italy
96 people with duodenal ulcer
Interventions PPI dual therapy (4 weeks lansoprazole 30 mg bd and 2 weeks amoxicillin 1 g tds) and
Bi quadruple therapy (4 weeks lansoprazole 30 mg od, 2 weeks bismuth 240 mg bd,
amoxicillin 1 g tds and tinidazole 500 mg bd) versus PPI (4 weeks lansoprazole 30 mg
od)
Outcomes Ulcer healing
H. pylori eradication rates
Notes Eradication rates:
PPI dual therapy 51.6%
Bi quadruple therapy 81.3%
PPI 3%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding was not performed
Incomplete outcome data (attrition bias)
All outcomes
High risk There were post-randomisation drop-outs
Selective reporting (reporting bias) Low risk Collected data was reported
Other bias Low risk There was no other bias
Pinero 1995
Methods Single-centre RCT
Unblinded
Participants Venezuela
60 people with duodenal ulcer
Interventions Bi triple therapy (2 weeks colloidal bismuth subcitrate 120 mg qds, amoxicillin 500 mg
tds and metronidazole 500 mg tds) versus PPI (4 weeks omeprazole 20 mg od)
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Pinero 1995 (Continued)
Outcomes Ulcer healing
Ulcer recurrence at 3 months
H. pylori eradication rates
Notes Eradication rates:
Bi triple therapy 63.3%
PPI 10%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding was not performed
Incomplete outcome data (attrition bias)
All outcomes
High risk There were post-randomisation drop-outs
Selective reporting (reporting bias) Unclear risk This information was not available
Other bias Low risk There was no other bias
Pounder 1997
Methods Multi-centre RCT
Double-blinded
Participants Multi-national
91 people with duodenal ulcer
Interventions RBC dual therapy (2 weeks RBC 400 mg/800 mg bd and clarithromycin 250 mg qds,
then 2 weeks RBC 400 mg bd) versus RBC (4 weeks 400 mg bd)
Outcomes Ulcer healing
Ulcer recurrence at 2 months
Global symptoms cured
H. pylori eradication rates
Notes Eradication rates:
RBC dual therapy 57.4%
RBC 0%
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Pounder 1997 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk “blinded study” “placebo capsules”
Incomplete outcome data (attrition bias)
All outcomes
High risk 10/95 (11%) lost to follow up
Selective reporting (reporting bias) Low risk Collected data was reported
Other bias Low risk There was no other bias
Rauws 1990
Methods Single-centre RCT
Single-blinded
Participants Netherlands
66 people with duodenal ulcer
Interventions Bi triple therapy (4 weeks colloidal bismuth subcitrate 120 mg qds and amoxicillin
375 mg tds, 10 days metronidazole 500 mg tds) versus Bi (4 weeks colloidal bismuth
subcitrate 120 mg qds)
Outcomes Ulcer healing
Ulcer recurrence at 1 year
H. pylori eradication rates
Notes Eradication rates:
Bi triple therapy 62.5%
Bi 7.7%
All participants received a further 4 weeks ranitidine 150 mg od
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
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Rauws 1990 (Continued)
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
High risk “open study”
Incomplete outcome data (attrition bias)
All outcomes
High risk 5/24 on triple therapy withdrew due to side effects,
11 others lost to follow up
Selective reporting (reporting bias) Low risk Collected data was reported
Other bias Low risk There was no other bias
Schwartz 1998
Methods Multi-centre RCT
Double-blinded
Participants USA
352 people with duodenal ulcer
Interventions PPI dual therapy (2 weeks lansoprazole 30 mg bd and clarithromycin 500 mg bd/tds or
2 weeks lansoprazole 30 mg bd/tds and amoxicillin 1 g tds) and triple therapy (2 weeks
lansoprazole 30 mg bd, amoxicillin 1 g bd and clarithromycin 500 mg bd) versus PPI (2
weeks lansoprazole 30 mg tds)
Outcomes Ulcer healing
Ulcer recurrence at 6 months
H. pylori eradication rates
Notes Eradication rates:
PPI dual therapy 65.5%
PPI triple therapy 93.6%
PPI 1.9%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk “all study medication was matched with placebo
to maintain the double-blind nature of the study”
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Schwartz 1998 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk This information was not available
Selective reporting (reporting bias) Low risk Collected data was reported
Other bias Low risk There was no other bias
Shirotani 1996
Methods Single-centre RCT
Single-blinded
Participants Japan
50 people with duodenal ulcer
Interventions H2RA triple therapy (6 weeks cimetidine 400 mg bd, 2 weeks amoxicillin 300 mg tds
and metronidazole 250 mg tds) versus H2RA (6 weeks cimetidine 400 mg bd)
Outcomes Ulcer healing
Ulcer recurrence at 6 months
H. pylori eradication rates
Notes Eradication rates:
H2RA triple therapy 56%
H2RA 0%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk “endoscopic examinations were ultimately judged
by an experienced endoscopist who was also not
informed of the treatment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 8/50 (16%) were lost to follow up
Selective reporting (reporting bias) Low risk Collected data was reported
Other bias Low risk There was no other bias
68Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Sobhani 1995
Methods Multi-centre RCT
Double-blinded
Participants France
119 people with duodenal ulcer
Interventions H2RA triple therapy (6 weeks famotidine 40 mg od, 1 week amoxicillin 500 mg qds
and tinidazole 500 mg tds) versus H2RA (6 weeks famotidine 40 mg od then 20 weeks
20 mg od)
Outcomes Ulcer healing
Ulcer recurrence at 6 months
H. pylori eradication rates
Notes Eradication rates:
H2RA triple therapy 42.4%
H2RA 1.7%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk “double blind, double dummy”
Incomplete outcome data (attrition bias)
All outcomes
High risk 9/97 (9%) of healed ulcer participants were lost
to follow up over 6 months
Selective reporting (reporting bias) Low risk Collected data was reported
Other bias Low risk There was no other bias
Spinzi 1994
Methods Multi-centre RCT
Unblinded
Participants Italy
53 people with duodenal ulcer
Interventions PPI dual therapy (4 weeks omeprazole 20 mg od, 2 weeks amoxicillin 1 g bd) versus PPI
(4 weeks omeprazole 20 mg od)
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Spinzi 1994 (Continued)
Outcomes Ulcer healing
Ulcer recurrence at 6 months
H. pylori eradication rates
Notes Eradication rates:
PPI dual therapy 41.7%
PPI 6.9%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding was not performed
Incomplete outcome data (attrition bias)
All outcomes
High risk 3/53 (6%) dropped out
Selective reporting (reporting bias) Low risk Collected data was reported
Other bias Low risk There was no other bias
Suarez 1999
Methods Single-centre RCT
Unblinded
Participants Cuba
60 people with gastric and duodenal ulcer
Interventions Bi triple therapy (6 weeks colloidal bismuth subcitrate 240 mg bd, 10 days metronidazole
500 mg tds and tetracycline 500 mg tds/amoxicillin 750 mg bd) versus Bi (6 weeks
colloidal bismuth subcitrate 240 mg bd)
Outcomes Ulcer healing
Global symptoms cured
H. pylori eradication rates
Notes Eradication rates:
Bi triple therapy 22.5%
Bi 0%
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Suarez 1999 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding was not performed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 7/60 (12%) drop-outs
Selective reporting (reporting bias) Low risk Collected data was reported
Other bias Low risk There was no other bias
Sung 1995
Methods Single-centre RCT
Unblinded
Participants Hong Kong
96 people with gastric ulcer
Interventions Bi triple therapy (1 week colloidal bismuth subcitrate 120 mg qds, tetracycline 500 mg
qds and metronidazole 400 mg qds) versus PPI (4 weeks omeprazole 20 mg od)
Outcomes Ulcer healing
Ulcer recurrence at 1 year
H. pylori eradication rates
Notes Eradication rates:
Bi triple therapy 80.4%
PPI 11.1%
If no healing at 4 weeks triple therapy participants received antacids and PPI participants
received further PPI
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk treatment assignments were determined with a list of
random numbers generated by computer
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Sung 1995 (Continued)
Allocation concealment (selection bias) Low risk “randomly assigned to one of two treatment groups
with the use of sealed envelopes”
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding was not performed
Incomplete outcome data (attrition bias)
All outcomes
High risk 85/100 (85%) completed the trial
Selective reporting (reporting bias) High risk Symptom data collected but not reported in sufficient
detail
Other bias Low risk There was no other bias
Tomita 2002
Methods Single-centre RCT
Unblinded
Participants Japan
445 people with gastric or duodenal ulcer
Interventions PPI triple therapy (6 weeks (DU) / 8 weeks (GU) lansoprazole 30 mg od or omeprazole
20 mg od, 2 weeks amoxicillin 1.5 g od and clarithromycin 400 mg od) versus PPI (6
weeks (DU) / 8 weeks (GU) lansoprazole 30 mg od or omeprazole 20 mg od) or H2RA
(6 weeks (DU) / 8 weeks (GU) famotidine 40 mg od or cimetidine 800 mg od)
Outcomes Ulcer recurrence at 5 years
H. pylori eradication rates
Notes Eradication rates:
PPI triple therapy 81.9%
PPI / H2RA 0%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding was not performed
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Tomita 2002 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk 32/445 (7%) loss to follow up
Selective reporting (reporting bias) High risk Symptom data collected but not reported
Other bias Low risk There was no other bias
Tulassay 2008
Methods Multi-centre RCT
Double-blinded
Participants Bulgaria, Czech Republic, Germany, Hong Kong, Hungary, Philippines, Poland, Roma-
nia, and Slovakia
402 people with gastric ulcer
Interventions PPI triple therapy (1 week esomeprazole 20 mg bd, amoxicillin 1 g bd, clarithromycin
500 mg bd followed by either 3 weeks of esomeprazole 20 mg od or placebo) versus PPI
(1 week of esomeprazole 20 mg bd followed by 3 weeks of esomeprazole 20 mg od)
Outcomes Ulcer healing
Ulcer recurrence at 12 months
H. pylori eradication rates
Notes Eradication rates:
PPI triple therapy 79.2%
PPI 9.5%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “randomised according to a computer-generated
list”
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk “to maintain blinding, the active and placebo
tablets were identical in terms of appearance, taste
and smell, as well as packaging and labelling”
Incomplete outcome data (attrition bias)
All outcomes
High risk 14/480 (3%) no primary end point data
Selective reporting (reporting bias) Low risk Collected data was reported
Other bias Low risk There was no other bias
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Unge 1993
Methods Multi-centre RCT
Double-blinded
Participants Sweden
233 people with duodenal ulcer
Interventions PPI dual therapy (4 weeks omeprazole 40 mg od and 2 weeks amoxicillin 750 mg bd)
versus PPI (4 weeks omeprazole 40 mg od)
Outcomes Ulcer recurrence at 6 months
H. pylori eradication rates
Notes Eradication rates:
PPI dual therapy 53.5%
PPI 3.9%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk “double blind and used a single placebo tech-
nique”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk This information was not available
Selective reporting (reporting bias) Low risk Collected data was reported
Other bias Low risk There was no other bias
Van Zanten 1999
Methods Multi-centre RCT
Double-blinded
Participants Canada
146 people with duodenal ulcer
Interventions PPI triple therapy (1 week omeprazole 20 mg bd, amoxicillin 1 g bd and clarithromycin
500mgbdor 1week omeprazole 20mgbd,metronidazole 400mgbd and clarithromycin
250 mg bd then 3 weeks omeprazole 20 mg od) versus PPI (4 weeks omeprazole 20 mg
od)
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Van Zanten 1999 (Continued)
Outcomes Ulcer healing
Ulcer recurrence at 6 months
H. pylori eradication
Notes Eradication rates:
PPI triple therapy 81.6%
PPI 0%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk Blinding was performed
Incomplete outcome data (attrition bias)
All outcomes
High risk 17/146 (12%) loss to follow up (n = 9) or not
included in ulcer relapse analysis (n = 8)
Selective reporting (reporting bias) Low risk Collected data was reported
Other bias Low risk There was no other bias
Wang 1993
Methods Single-centre RCT
Unblinded
Participants Taiwan
59 people with duodenal ulcer
Interventions Bi triple therapy (4 weeks colloidal bismuth subcitrate 120 mg qds, 2 weeks tetracycline
500 mg qds and metronidazole 250 mg qds) versus H2RA (4 weeks ranitidine 150 mg
bd) and Bi (4 weeks colloidal bismuth subcitrate 120 mg qds)
Outcomes Ulcer healing
Ulcer recurrence at 6 months
H. pylori eradication rates
Notes Eradication rates:
Bi triple therapy 82.6%
H2RA 0%
Bi 0%
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Wang 1993 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding was not performed
Incomplete outcome data (attrition bias)
All outcomes
High risk There were post-randomisation drop-outs
Selective reporting (reporting bias) High risk H2RA given until ulcers healed but these data were
not given
Other bias Low risk There was no other bias
Wang 1996
Methods Single-centre RCT
Unblinded
Participants Taiwan
112 people with gastric and duodenal ulcer
Interventions Bi triple therapy (4 weeks colloidal bismuth subcitrate 300 mg qds, 1 week amoxicillin
750 mg bd and metronidazole 500 mg tds) and PPI dual therapy (4 weeks omeprazole
20 mg bd/qds and 10 days amoxicillin 750 mg bd) versus PPI (4 weeks omeprazole 20
mg qds) and H2RA (4 weeks nizatidine/ranitidine 150 mg bd)
Outcomes Ulcer healing
H. pylori eradication rates
Notes Eradication rates:
Bi triple therapy 68%
PPI dual therapy 50%
PPI 4.5%
H2RA 0%
All participants received 4 weeks H2RA after initial therapy
Risk of bias
Bias Authors’ judgement Support for judgement
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Wang 1996 (Continued)
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding was not performed
Incomplete outcome data (attrition bias)
All outcomes
High risk There were post-randomisation drop-outs
Selective reporting (reporting bias) Low risk Collected data was reported
Other bias High risk Reported according to H. pylori status and not ran-
domised groups
Wong 1999
Methods Single-centre RCT
Single-blinded
Participants Hong Kong
114 people with duodenal ulcer
Interventions Clarithromycin monotherapy (2 weeks 250 mg qds) versus PPI (1 year omeprazole 20
mg od)
Outcomes Ulcer healing
Ulcer recurrence at 1 year
H. pylori eradication rates
Notes Eradication rates:
Clarithromycin monotherapy 66.7%
PPI 7%
Clarithromycin participants also received 4 weeks sucralfate 1 g qds and 2 weeks metron-
idazole 300 mg qds
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available
Allocation concealment (selection bias) Unclear risk This information was not available
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Wong 1999 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk “the endoscopists were blinded to the treatment
type and any clinical information related to the
patients”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 15/114 (13%) drop-outs
Selective reporting (reporting bias) High risk Symptom data collected but not reported
Other bias Low risk There was no other bias
bd: twice per day
od: once per day
qds: four times per day
tds: three times per day
Bi quadruple therapy: Bismuth quadruple therapy
PPI: proton pump inhibitor
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Al-Assi 1995 No ulcer healing or recurrence data
Bytzer 2000 Not all participants were H. pylori positive, and no way of extracting data for just the H. pylori-
positive participants
Dogan 1997 Control arm of the trial were all H. pylori negative
Dumbleton 2015 Not participants with peptic ulcer disease
Gisbert 2000 No ulcer healing or recurrence data
Hosking 1994 No comparative intervention
Kohli 1995 Not truly randomised
Labenz 1993 No ulcer healing or recurrence data
Laine 2000 No ulcer healing or recurrence data
Lind 1996 No ulcer healing or recurrence data
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(Continued)
Malfertheiner 2002a No ulcer healing or recurrence data
Nakata 1995 Not truly randomised
O’Riordan 1990 Not truly randomised
Parente 1998 Not truly randomised
Peterson 1996 Not all participants were H. pylori-positive, and no way of extracting data for just the H. pylori-
positive participants
Prach 1998 Not all participants had documented peptic ulcer disease
Rune 1993 Not a recognised eradication regimen
Shimoyama 1995 Not truly randomised
Sonnenberg 1998 No ulcer healing or recurrence data
Sonnenberg 1999 No ulcer healing or recurrence data
Sugiyama 1995 Not truly randomised
Tavakoli 1999 No ulcer healing or recurrence data
Tham 1996 Not participants with peptic ulcer disease
Veldhuyzen Van Zanten 2000 Not all participants had documented peptic ulcer disease
Xia 1995 Not truly randomised
79Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. H. pylori eradication + ulcer healing drug vs. ulcer healing drug alone: duodenal ulcer acute
healing
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion not healed 34 3910 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.58, 0.76]
Comparison 2. H. pylori eradication vs. no treatment/placebo: duodenal ulcer acute healing
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion not healed 2 207 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.26, 0.53]
Comparison 3. H. pylori eradication + ulcer healing drug vs. ulcer healing drug alone: gastric ulcer acute healing
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion not healed 15 1974 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.90, 1.68]
Comparison 4. H. pylori eradication + ulcer healing drug vs. ulcer healing drug alone: peptic ulcer acute healing
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion not healed 3 287 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.31, 0.85]
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Comparison 5. H. pylori eradication vs. no treatment/placebo: peptic ulcer acute healing
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion not healed 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 6. H. pylori eradication vs. ulcer healing drug alone (after initial ulcer healing): duodenal ulcer
recurrence
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion recurred 4 319 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.42, 1.25]
Comparison 7. H. pylori eradication vs. no treatment (after initial ulcer healing): duodenal ulcer recurrence
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion recurred 27 2509 Risk Ratio (M-H, Random, 95% CI) 0.20 [0.15, 0.26]
Comparison 8. H. pylori eradication vs. no treatment (after initial ulcer healing): gastric ulcer recurrence
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion recurred 12 1476 Risk Ratio (M-H, Random, 95% CI) 0.31 [0.22, 0.45]
Comparison 9. H. pylori eradication vs. no treatment (after initial ulcer healing): peptic ulcer recurrence
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion recurred 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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Comparison 10. Global symptoms persisting
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 H. pylori eradication + ulcer
healing drug vs. ulcer healing
drug alone
2 180 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.42, 1.74]
2 H. pylori eradication vs. no
treatment
2 188 Risk Ratio (M-H, Random, 95% CI) 1.27 [0.83, 1.93]
Comparison 11. Adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall, proportion occurred 43 6093 Risk Ratio (M-H, Random, 95% CI) 2.30 [1.77, 2.99]
2 Diarrhoea, proportion occurred 30 4590 Risk Ratio (M-H, Fixed, 95% CI) 2.86 [2.11, 3.88]
3 Nausea/vomiting, proportion
occurred
15 1533 Risk Ratio (M-H, Fixed, 95% CI) 3.76 [1.91, 7.37]
4 Skin rash, proportion occurred 18 2385 Risk Ratio (M-H, Fixed, 95% CI) 1.36 [0.78, 2.37]
5 Headache, proportion occurred 14 2292 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.70, 1.75]
6 Epigastric pain, proportion
occurred
11 1491 Risk Ratio (M-H, Fixed, 95% CI) 4.09 [1.90, 8.82]
7 Altered taste, proportion
occurred
13 2299 Risk Ratio (M-H, Fixed, 95% CI) 8.85 [4.38, 17.90]
8 Stomatitis, proportion occurred
versus not occurred
8 838 Risk Ratio (M-H, Fixed, 95% CI) 2.65 [0.94, 7.48]
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Analysis 1.1. Comparison 1 H. pylori eradication + ulcer healing drug vs. ulcer healing drug alone: duodenal
ulcer acute healing, Outcome 1 Proportion not healed.
Review: Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people
Comparison: 1 H. pylori eradication + ulcer healing drug vs. ulcer healing drug alone: duodenal ulcer acute healing
Outcome: 1 Proportion not healed
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Asaka 2001 34/205 10/51 4.5 % 0.85 [ 0.45, 1.60 ]
Avsar 1996 2/23 10/22 2.9 % 0.19 [ 0.05, 0.78 ]
Bardhan 1997 4/141 6/74 2.2 % 0.35 [ 0.10, 1.20 ]
Bayerdorffer 1992 2/29 4/29 1.1 % 0.50 [ 0.10, 2.52 ]
Bayerdorffer 1995 4/136 12/128 3.5 % 0.31 [ 0.10, 0.95 ]
Bianchi Porro 1993 7/91 12/92 3.4 % 0.59 [ 0.24, 1.43 ]
Bianchi Porro 1996 2/17 9/15 2.7 % 0.20 [ 0.05, 0.77 ]
Carpintero 1997 3/78 3/44 1.1 % 0.56 [ 0.12, 2.68 ]
Figueroa 1996 4/57 4/43 1.3 % 0.75 [ 0.20, 2.85 ]
Furuta 1995 0/20 0/20 Not estimable
Graham 1991 4/53 10/52 2.8 % 0.39 [ 0.13, 1.17 ]
Graham 1998 22/77 27/76 7.6 % 0.80 [ 0.51, 1.28 ]
Harford 1996 36/127 25/69 9.1 % 0.78 [ 0.52, 1.19 ]
Hentschel 1993 1/52 3/52 0.8 % 0.33 [ 0.04, 3.10 ]
Hosking 1992 8/78 21/77 5.9 % 0.38 [ 0.18, 0.80 ]
Kato 1996 0/28 1/23 0.5 % 0.28 [ 0.01, 6.47 ]
Katoh 1995 0/27 1/25 0.4 % 0.31 [ 0.01, 7.26 ]
Kepecki 1999 7/39 4/34 1.2 % 1.53 [ 0.49, 4.77 ]
Lin 1994 0/21 2/21 0.7 % 0.20 [ 0.01, 3.93 ]
Logan 1995 2/70 6/78 1.6 % 0.37 [ 0.08, 1.78 ]
Mantzaris 1993 5/17 8/16 2.3 % 0.59 [ 0.24, 1.42 ]
Mones 2001 5/42 7/43 1.9 % 0.73 [ 0.25, 2.12 ]
O’Morain 1996 9/102 15/106 4.1 % 0.62 [ 0.29, 1.36 ]
Parente 1996 7/63 1/33 0.4 % 3.67 [ 0.47, 28.55 ]
Pinero 1995 8/30 7/30 2.0 % 1.14 [ 0.47, 2.75 ]
0.1 0.2 0.5 1 2 5 10
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pounder 1997 5/61 8/30 3.0 % 0.31 [ 0.11, 0.86 ]
Rauws 1990 7/24 5/26 1.4 % 1.52 [ 0.56, 4.14 ]
Schwartz 1998 168/292 44/60 20.5 % 0.78 [ 0.65, 0.94 ]
Shirotani 1996 4/25 6/25 1.7 % 0.67 [ 0.21, 2.08 ]
Sobhani 1995 7/59 15/60 4.2 % 0.47 [ 0.21, 1.08 ]
Spinzi 1994 2/24 3/29 0.8 % 0.81 [ 0.15, 4.43 ]
Van Zanten 1999 0/98 3/48 1.3 % 0.07 [ 0.00, 1.34 ]
Wang 1993 3/23 6/36 1.3 % 0.78 [ 0.22, 2.82 ]
Wong 1999 9/57 6/57 1.7 % 1.50 [ 0.57, 3.94 ]
Total (95% CI) 2286 1624 100.0 % 0.66 [ 0.58, 0.76 ]
Total events: 381 (Treatment), 304 (Control)
Heterogeneity: Chi2 = 36.30, df = 32 (P = 0.27); I2 =12%
Test for overall effect: Z = 5.96 (P < 0.00001)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
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Analysis 2.1. Comparison 2 H. pylori eradication vs. no treatment/placebo: duodenal ulcer acute healing,
Outcome 1 Proportion not healed.
Review: Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people
Comparison: 2 H. pylori eradication vs. no treatment/placebo: duodenal ulcer acute healing
Outcome: 1 Proportion not healed
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Graham 1998 22/77 25/33 60.6 % 0.38 [ 0.25, 0.56 ]
Lam 1997 8/48 23/49 39.4 % 0.36 [ 0.18, 0.71 ]
Total (95% CI) 125 82 100.0 % 0.37 [ 0.26, 0.53 ]
Total events: 30 (Treatment), 48 (Control)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 5.35 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 H. pylori eradication + ulcer healing drug vs. ulcer healing drug alone: gastric
ulcer acute healing, Outcome 1 Proportion not healed.
Review: Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people
Comparison: 3 H. pylori eradication + ulcer healing drug vs. ulcer healing drug alone: gastric ulcer acute healing
Outcome: 1 Proportion not healed
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Asaka 2001 65/225 11/55 12.1 % 1.44 [ 0.82, 2.55 ]
Axon 1997 20/87 13/42 11.6 % 0.74 [ 0.41, 1.34 ]
Bayerdorffer 1996 13/65 3/65 5.0 % 4.33 [ 1.30, 14.49 ]
Befrits 2004 10/56 11/47 9.1 % 0.76 [ 0.36, 1.64 ]
Fukuda 1995a 0/32 1/33 0.9 % 0.34 [ 0.01, 8.13 ]
Fukuda 1995b 0/37 1/49 0.9 % 0.44 [ 0.02, 10.47 ]
Furuta 1995 0/12 2/15 1.1 % 0.25 [ 0.01, 4.69 ]
Higuchi 2003 31/61 10/59 11.3 % 3.00 [ 1.62, 5.55 ]
Kato 1996 5/35 3/33 4.2 % 1.57 [ 0.41, 6.06 ]
Katoh 1995 7/40 3/39 4.6 % 2.28 [ 0.63, 8.17 ]
Lazzaroni 1997 0/29 2/30 1.0 % 0.21 [ 0.01, 4.13 ]
Malfertheiner 1999 20/97 10/48 10.3 % 0.99 [ 0.50, 1.95 ]
Meining 1998 23/100 15/85 11.8 % 1.30 [ 0.73, 2.33 ]
Sung 1995 6/51 7/45 6.4 % 0.76 [ 0.27, 2.08 ]
Tulassay 2008 20/265 10/137 9.6 % 1.03 [ 0.50, 2.15 ]
Total (95% CI) 1192 782 100.0 % 1.23 [ 0.90, 1.68 ]
Total events: 220 (Treatment), 102 (Control)
Heterogeneity: Tau2 = 0.13; Chi2 = 22.93, df = 14 (P = 0.06); I2 =39%
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 H. pylori eradication + ulcer healing drug vs. ulcer healing drug alone: peptic
ulcer acute healing, Outcome 1 Proportion not healed.
Review: Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people
Comparison: 4 H. pylori eradication + ulcer healing drug vs. ulcer healing drug alone: peptic ulcer acute healing
Outcome: 1 Proportion not healed
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arkkila 2005 3/85 6/30 29.0 % 0.18 [ 0.05, 0.66 ]
Suarez 1999 11/40 8/20 34.8 % 0.69 [ 0.33, 1.43 ]
Wang 1996 9/69 9/43 36.2 % 0.62 [ 0.27, 1.45 ]
Total (95% CI) 194 93 100.0 % 0.52 [ 0.31, 0.85 ]
Total events: 23 (Treatment), 23 (Control)
Heterogeneity: Chi2 = 3.31, df = 2 (P = 0.19); I2 =40%
Test for overall effect: Z = 2.59 (P = 0.0095)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
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Analysis 5.1. Comparison 5 H. pylori eradication vs. no treatment/placebo: peptic ulcer acute healing,
Outcome 1 Proportion not healed.
Review: Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people
Comparison: 5 H. pylori eradication vs. no treatment/placebo: peptic ulcer acute healing
Outcome: 1 Proportion not healed
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Feng 2005 3/25 12/15 0.15 [ 0.05, 0.45 ]
0.001 0.01 0.1 1 10 100 1000
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Analysis 6.1. Comparison 6 H. pylori eradication vs. ulcer healing drug alone (after initial ulcer healing):
duodenal ulcer recurrence, Outcome 1 Proportion recurred.
Review: Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people
Comparison: 6 H. pylori eradication vs. ulcer healing drug alone (after initial ulcer healing): duodenal ulcer recurrence
Outcome: 1 Proportion recurred
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kepecki 1999 7/29 5/30 18.8 % 1.45 [ 0.52, 4.05 ]
Mones 2001 4/37 4/36 15.5 % 0.97 [ 0.26, 3.60 ]
Sobhani 1995 6/45 12/43 47.0 % 0.48 [ 0.20, 1.16 ]
Wong 1999 2/48 5/51 18.6 % 0.43 [ 0.09, 2.09 ]
Total (95% CI) 159 160 100.0 % 0.73 [ 0.42, 1.25 ]
Total events: 19 (Treatment), 26 (Control)
Heterogeneity: Chi2 = 3.22, df = 3 (P = 0.36); I2 =7%
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 7.1. Comparison 7 H. pylori eradication vs. no treatment (after initial ulcer healing): duodenal
ulcer recurrence, Outcome 1 Proportion recurred.
Review: Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people
Comparison: 7 H. pylori eradication vs. no treatment (after initial ulcer healing): duodenal ulcer recurrence
Outcome: 1 Proportion recurred
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Avsar 1996 3/17 6/10 3.1 % 0.29 [ 0.09, 0.92 ]
Bardhan 1997 10/133 25/63 4.8 % 0.19 [ 0.10, 0.37 ]
Bayerdorffer 1992 6/26 19/25 4.5 % 0.30 [ 0.15, 0.63 ]
Bayerdorffer 1995 15/132 51/116 5.4 % 0.26 [ 0.15, 0.43 ]
Bianchi Porro 1996 8/71 52/66 4.8 % 0.14 [ 0.07, 0.28 ]
Carpintero 1997 31/72 34/39 6.3 % 0.49 [ 0.37, 0.66 ]
Chen 1995 10/31 27/29 5.4 % 0.35 [ 0.21, 0.58 ]
Figueroa 1996 3/53 34/39 3.2 % 0.06 [ 0.02, 0.20 ]
Graham 1992 6/47 34/36 4.4 % 0.14 [ 0.06, 0.29 ]
Hentschel 1993 4/50 42/49 3.7 % 0.09 [ 0.04, 0.24 ]
Hosking 1992 2/61 22/45 2.4 % 0.07 [ 0.02, 0.27 ]
Kato 1996 3/27 12/18 3.2 % 0.17 [ 0.05, 0.51 ]
Kim 2002 2/36 5/17 2.1 % 0.19 [ 0.04, 0.88 ]
Lin 1994 1/18 11/18 1.5 % 0.09 [ 0.01, 0.63 ]
Logan 1995 3/51 47/62 3.2 % 0.08 [ 0.03, 0.23 ]
Mantzaris 1993 2/12 6/8 2.6 % 0.22 [ 0.06, 0.84 ]
O’Morain 1996 8/78 41/82 4.7 % 0.21 [ 0.10, 0.41 ]
Pinero 1995 3/19 13/20 3.2 % 0.24 [ 0.08, 0.72 ]
Pounder 1997 0/56 4/22 0.8 % 0.04 [ 0.00, 0.80 ]
Rauws 1990 1/17 16/21 1.5 % 0.08 [ 0.01, 0.52 ]
Schwartz 1998 19/124 11/16 5.4 % 0.22 [ 0.13, 0.38 ]
Shirotani 1996 2/18 9/14 2.5 % 0.17 [ 0.04, 0.68 ]
Spinzi 1994 3/22 15/26 3.2 % 0.24 [ 0.08, 0.71 ]
Tomita 2002 11/55 20/20 5.4 % 0.21 [ 0.13, 0.35 ]
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Unge 1993 48/157 50/76 6.3 % 0.46 [ 0.35, 0.62 ]
Van Zanten 1999 10/98 25/45 4.9 % 0.18 [ 0.10, 0.35 ]
Wang 1993 1/20 18/26 1.5 % 0.07 [ 0.01, 0.50 ]
Total (95% CI) 1501 1008 100.0 % 0.20 [ 0.15, 0.26 ]
Total events: 215 (Treatment), 649 (Control)
Heterogeneity: Tau2 = 0.28; Chi2 = 85.11, df = 26 (P<0.00001); I2 =69%
Test for overall effect: Z = 11.74 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 8.1. Comparison 8 H. pylori eradication vs. no treatment (after initial ulcer healing): gastric ulcer
recurrence, Outcome 1 Proportion recurred.
Review: Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people
Comparison: 8 H. pylori eradication vs. no treatment (after initial ulcer healing): gastric ulcer recurrence
Outcome: 1 Proportion recurred
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Axon 1997 16/72 17/35 11.6 % 0.46 [ 0.26, 0.79 ]
Bayerdorffer 1996 4/52 34/62 7.4 % 0.14 [ 0.05, 0.37 ]
Befrits 2004 10/42 24/33 11.2 % 0.33 [ 0.18, 0.58 ]
Fukuda 1995b 3/36 19/48 6.2 % 0.21 [ 0.07, 0.66 ]
Graham 1992 2/15 8/11 5.0 % 0.18 [ 0.05, 0.70 ]
Kato 1996 8/28 11/26 9.5 % 0.68 [ 0.32, 1.41 ]
Lazzaroni 1997 6/28 16/24 9.3 % 0.32 [ 0.15, 0.69 ]
Malfertheiner 1999 12/97 13/48 9.9 % 0.46 [ 0.23, 0.92 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Meining 1998 0/77 10/70 1.5 % 0.04 [ 0.00, 0.73 ]
Sung 1995 1/22 12/23 2.8 % 0.09 [ 0.01, 0.62 ]
Tomita 2002 14/83 156/172 12.3 % 0.19 [ 0.12, 0.30 ]
Tulassay 2008 40/245 36/127 13.3 % 0.58 [ 0.39, 0.86 ]
Total (95% CI) 797 679 100.0 % 0.31 [ 0.22, 0.45 ]
Total events: 116 (Treatment), 356 (Control)
Heterogeneity: Tau2 = 0.22; Chi2 = 29.09, df = 11 (P = 0.002); I2 =62%
Test for overall effect: Z = 6.27 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 9.1. Comparison 9 H. pylori eradication vs. no treatment (after initial ulcer healing): peptic ulcer
recurrence, Outcome 1 Proportion recurred.
Review: Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people
Comparison: 9 H. pylori eradication vs. no treatment (after initial ulcer healing): peptic ulcer recurrence
Outcome: 1 Proportion recurred
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arkkila 2005 6/79 8/24 0.23 [ 0.09, 0.59 ]
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Analysis 10.1. Comparison 10 Global symptoms persisting, Outcome 1 H. pylori eradication + ulcer healing
drug vs. ulcer healing drug alone.
Review: Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people
Comparison: 10 Global symptoms persisting
Outcome: 1 H. pylori eradication + ulcer healing drug vs. ulcer healing drug alone
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Higuchi 2003 29/61 45/59 55.4 % 0.62 [ 0.46, 0.84 ]
Suarez 1999 23/40 9/20 44.6 % 1.28 [ 0.74, 2.22 ]
Total (95% CI) 101 79 100.0 % 0.86 [ 0.42, 1.74 ]
Total events: 52 (Treatment), 54 (Control)
Heterogeneity: Tau2 = 0.21; Chi2 = 5.07, df = 1 (P = 0.02); I2 =80%
Test for overall effect: Z = 0.42 (P = 0.67)
Test for subgroup differences: Not applicable
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Analysis 10.2. Comparison 10 Global symptoms persisting, Outcome 2 H. pylori eradication vs. no
treatment.
Review: Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people
Comparison: 10 Global symptoms persisting
Outcome: 2 H. pylori eradication vs. no treatment
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lam 1997 34/48 22/49 44.0 % 1.58 [ 1.10, 2.26 ]
Pounder 1997 52/61 24/30 56.0 % 1.07 [ 0.87, 1.31 ]
Total (95% CI) 109 79 100.0 % 1.27 [ 0.83, 1.93 ]
Total events: 86 (Treatment), 46 (Control)
Heterogeneity: Tau2 = 0.07; Chi2 = 4.19, df = 1 (P = 0.04); I2 =76%
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Not applicable
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Analysis 11.1. Comparison 11 Adverse events, Outcome 1 Overall, proportion occurred.
Review: Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people
Comparison: 11 Adverse events
Outcome: 1 Overall, proportion occurred
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Arkkila 2005 21/85 1/30 1.4 % 7.41 [ 1.04, 52.75 ]
Asaka 2001 217/430 42/106 7.2 % 1.27 [ 0.99, 1.64 ]
Avsar 1996 0/23 0/22 Not estimable
Axon 1997 0/87 1/42 0.6 % 0.16 [ 0.01, 3.92 ]
Bardhan 1997 25/141 15/74 5.6 % 0.87 [ 0.49, 1.55 ]
Bayerdorffer 1992 0/29 1/29 0.6 % 0.33 [ 0.01, 7.86 ]
Bayerdorffer 1995 11/136 3/128 2.8 % 3.45 [ 0.99, 12.09 ]
Bayerdorffer 1996 16/65 0/65 0.8 % 33.00 [ 2.02, 538.74 ]
Befrits 2004 27/56 19/47 6.3 % 1.19 [ 0.77, 1.85 ]
Bianchi Porro 1996 11/91 7/92 4.0 % 1.59 [ 0.64, 3.92 ]
Carpintero 1997 13/78 1/44 1.4 % 7.33 [ 0.99, 54.19 ]
Chen 1995 24/49 0/29 0.8 % 29.40 [ 1.85, 465.97 ]
Fukuda 1995a 0/32 0/33 Not estimable
Fukuda 1995b 1/37 0/49 0.6 % 3.95 [ 0.17, 94.23 ]
Graham 1991 6/53 0/52 0.8 % 12.76 [ 0.74, 220.88 ]
Graham 1998 7/77 7/109 3.6 % 1.42 [ 0.52, 3.87 ]
Harford 1996 24/127 5/69 3.9 % 2.61 [ 1.04, 6.53 ]
Hentschel 1993 8/52 1/52 1.4 % 8.00 [ 1.04, 61.71 ]
Higuchi 2003 11/61 1/59 1.4 % 10.64 [ 1.42, 79.85 ]
Hosking 1992 6/78 6/77 3.3 % 0.99 [ 0.33, 2.93 ]
Kato 1996 4/63 0/56 0.7 % 8.02 [ 0.44, 145.66 ]
Lam 1997 2/48 0/49 0.7 % 5.10 [ 0.25, 103.58 ]
Lazzaroni 1997 4/29 2/30 2.0 % 2.07 [ 0.41, 10.44 ]
Lin 1994 5/21 0/21 0.8 % 11.00 [ 0.65, 187.17 ]
Logan 1995 28/70 23/78 6.3 % 1.36 [ 0.87, 2.12 ]
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Malfertheiner 1999 12/97 6/48 4.0 % 0.99 [ 0.40, 2.48 ]
Mantzaris 1993 3/17 0/16 0.7 % 6.61 [ 0.37, 118.73 ]
Meining 1998 23/100 5/85 3.9 % 3.91 [ 1.55, 9.84 ]
O’Morain 1996 38/102 13/106 5.6 % 3.04 [ 1.72, 5.36 ]
Parente 1996 6/63 0/33 0.8 % 6.91 [ 0.40, 118.94 ]
Pinero 1995 2/30 0/30 0.7 % 5.00 [ 0.25, 99.95 ]
Pounder 1997 21/61 7/30 4.8 % 1.48 [ 0.71, 3.08 ]
Rauws 1990 5/24 0/26 0.8 % 11.88 [ 0.69, 204.05 ]
Schwartz 1998 80/292 9/60 5.3 % 1.83 [ 0.97, 3.43 ]
Shirotani 1996 4/25 0/25 0.8 % 9.00 [ 0.51, 158.85 ]
Sobhani 1995 10/59 3/60 2.8 % 3.39 [ 0.98, 11.70 ]
Spinzi 1994 1/24 0/29 0.6 % 3.60 [ 0.15, 84.54 ]
Suarez 1999 11/40 3/20 3.1 % 1.83 [ 0.58, 5.84 ]
Sung 1995 5/51 0/45 0.8 % 9.73 [ 0.55, 171.24 ]
Tomita 2002 3/138 0/192 0.7 % 9.72 [ 0.51, 186.66 ]
Tulassay 2008 79/315 13/164 5.7 % 3.16 [ 1.82, 5.51 ]
Wang 1996 13/69 0/43 0.8 % 16.97 [ 1.03, 278.36 ]
Wong 1999 6/57 1/57 1.3 % 6.00 [ 0.75, 48.26 ]
Total (95% CI) 3582 2511 100.0 % 2.30 [ 1.77, 2.99 ]
Total events: 793 (Treatment), 195 (Control)
Heterogeneity: Tau2 = 0.23; Chi2 = 80.47, df = 40 (P = 0.00016); I2 =50%
Test for overall effect: Z = 6.22 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 11.2. Comparison 11 Adverse events, Outcome 2 Diarrhoea, proportion occurred.
Review: Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people
Comparison: 11 Adverse events
Outcome: 2 Diarrhoea, proportion occurred
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arkkila 2005 7/85 0/30 1.3 % 5.41 [ 0.32, 91.91 ]
Asaka 2001 38/430 7/106 19.6 % 1.34 [ 0.61, 2.91 ]
Bardhan 1997 9/141 3/74 6.9 % 1.57 [ 0.44, 5.64 ]
Bayerdorffer 1995 3/136 1/128 1.8 % 2.82 [ 0.30, 26.80 ]
Bayerdorffer 1996 6/65 0/65 0.9 % 13.00 [ 0.75, 226.12 ]
Bianchi Porro 1996 3/91 4/92 7.0 % 0.76 [ 0.17, 3.29 ]
Carpintero 1997 5/78 0/44 1.1 % 6.27 [ 0.35, 110.71 ]
Chen 1995 4/49 0/29 1.1 % 5.40 [ 0.30, 96.82 ]
Graham 1991 1/53 0/52 0.9 % 2.94 [ 0.12, 70.67 ]
Graham 1998 4/77 0/109 0.7 % 12.69 [ 0.69, 232.36 ]
Harford 1996 8/127 1/69 2.3 % 4.35 [ 0.56, 34.04 ]
Hentschel 1993 7/52 1/52 1.7 % 7.00 [ 0.89, 54.91 ]
Kato 1996 2/63 0/56 0.9 % 4.45 [ 0.22, 90.82 ]
Lam 1997 1/48 0/49 0.9 % 3.06 [ 0.13, 73.34 ]
Lazzaroni 1997 2/29 1/30 1.7 % 2.07 [ 0.20, 21.60 ]
Lin 1994 5/21 0/21 0.9 % 11.00 [ 0.65, 187.17 ]
Logan 1995 4/70 4/78 6.6 % 1.11 [ 0.29, 4.29 ]
Malfertheiner 1999 4/97 0/48 1.2 % 4.50 [ 0.25, 81.91 ]
Meining 1998 20/100 4/85 7.6 % 4.25 [ 1.51, 11.95 ]
O’Morain 1996 17/102 4/106 6.9 % 4.42 [ 1.54, 12.68 ]
Parente 1996 1/63 0/33 1.1 % 1.59 [ 0.07, 38.07 ]
Pounder 1997 3/61 0/30 1.2 % 3.50 [ 0.19, 65.66 ]
Rauws 1990 1/24 0/26 0.8 % 3.24 [ 0.14, 75.91 ]
Shirotani 1996 1/25 0/25 0.9 % 3.00 [ 0.13, 70.30 ]
Sobhani 1995 4/59 0/60 0.9 % 9.15 [ 0.50, 166.28 ]
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sung 1995 1/51 0/45 0.9 % 2.65 [ 0.11, 63.56 ]
Tulassay 2008 16/315 3/164 6.9 % 2.78 [ 0.82, 9.39 ]
Van Zanten 1999 28/98 5/48 11.7 % 2.74 [ 1.13, 6.66 ]
Wang 1996 3/69 0/43 1.1 % 4.40 [ 0.23, 83.15 ]
Wong 1999 0/57 1/57 2.6 % 0.33 [ 0.01, 8.01 ]
Total (95% CI) 2736 1854 100.0 % 2.86 [ 2.11, 3.88 ]
Total events: 208 (Treatment), 39 (Control)
Heterogeneity: Chi2 = 18.13, df = 29 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 6.79 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 11.3. Comparison 11 Adverse events, Outcome 3 Nausea/vomiting, proportion occurred.
Review: Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people
Comparison: 11 Adverse events
Outcome: 3 Nausea/vomiting, proportion occurred
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bayerdorffer 1995 2/136 1/128 9.3 % 1.88 [ 0.17, 20.51 ]
Bayerdorffer 1996 1/65 0/65 4.5 % 3.00 [ 0.12, 72.31 ]
Carpintero 1997 1/78 0/44 5.7 % 1.71 [ 0.07, 41.08 ]
Chen 1995 9/49 0/29 5.6 % 11.40 [ 0.69, 188.89 ]
Graham 1991 4/53 0/52 4.5 % 8.83 [ 0.49, 160.07 ]
Graham 1998 1/77 1/109 7.5 % 1.42 [ 0.09, 22.29 ]
Lazzaroni 1997 1/29 0/30 4.4 % 3.10 [ 0.13, 73.14 ]
Lin 1994 3/21 0/21 4.5 % 7.00 [ 0.38, 127.69 ]
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mantzaris 1993 2/17 0/16 4.6 % 4.72 [ 0.24, 91.41 ]
Rauws 1990 3/24 0/26 4.3 % 7.56 [ 0.41, 139.17 ]
Shirotani 1996 1/25 0/25 4.5 % 3.00 [ 0.13, 70.30 ]
Suarez 1999 5/40 0/20 6.0 % 5.63 [ 0.33, 97.10 ]
Sung 1995 2/51 0/45 4.8 % 4.42 [ 0.22, 89.76 ]
Van Zanten 1999 7/98 2/48 24.2 % 1.71 [ 0.37, 7.94 ]
Wang 1996 1/69 0/43 5.5 % 1.89 [ 0.08, 45.27 ]
Total (95% CI) 832 701 100.0 % 3.76 [ 1.91, 7.37 ]
Total events: 43 (Treatment), 4 (Control)
Heterogeneity: Chi2 = 3.72, df = 14 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 3.85 (P = 0.00012)
Test for subgroup differences: Not applicable
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Analysis 11.4. Comparison 11 Adverse events, Outcome 4 Skin rash, proportion occurred.
Review: Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people
Comparison: 11 Adverse events
Outcome: 4 Skin rash, proportion occurred
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arkkila 2005 4/85 1/30 7.1 % 1.41 [ 0.16, 12.14 ]
Bayerdorffer 1996 2/65 0/65 2.4 % 5.00 [ 0.24, 102.16 ]
Bianchi Porro 1996 0/91 2/92 11.9 % 0.20 [ 0.01, 4.15 ]
Carpintero 1997 1/78 0/44 3.1 % 1.71 [ 0.07, 41.08 ]
Chen 1995 3/49 0/29 3.0 % 4.20 [ 0.22, 78.53 ]
Harford 1996 3/127 1/69 6.2 % 1.63 [ 0.17, 15.37 ]
Hentschel 1993 1/52 0/52 2.4 % 3.00 [ 0.13, 71.99 ]
Higuchi 2003 1/61 0/59 2.4 % 2.90 [ 0.12, 69.87 ]
Kato 1996 1/63 0/56 2.5 % 2.67 [ 0.11, 64.29 ]
Lam 1997 1/48 0/49 2.4 % 3.06 [ 0.13, 73.34 ]
Logan 1995 2/70 2/78 9.1 % 1.11 [ 0.16, 7.70 ]
Malfertheiner 1999 0/97 1/48 9.6 % 0.17 [ 0.01, 4.02 ]
Meining 1998 2/100 1/85 5.2 % 1.70 [ 0.16, 18.42 ]
Pounder 1997 0/61 3/30 22.4 % 0.07 [ 0.00, 1.34 ]
Rauws 1990 1/24 0/26 2.3 % 3.24 [ 0.14, 75.91 ]
Suarez 1999 2/40 0/20 3.2 % 2.56 [ 0.13, 50.95 ]
Tomita 2002 1/138 0/192 2.0 % 4.17 [ 0.17, 101.49 ]
Wang 1996 2/69 0/43 2.9 % 3.14 [ 0.15, 63.94 ]
Total (95% CI) 1318 1067 100.0 % 1.36 [ 0.78, 2.37 ]
Total events: 27 (Treatment), 11 (Control)
Heterogeneity: Chi2 = 10.60, df = 17 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.08 (P = 0.28)
Test for subgroup differences: Not applicable
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Analysis 11.5. Comparison 11 Adverse events, Outcome 5 Headache, proportion occurred.
Review: Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people
Comparison: 11 Adverse events
Outcome: 5 Headache, proportion occurred
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bardhan 1997 8/141 7/74 27.1 % 0.60 [ 0.23, 1.59 ]
Bayerdorffer 1992 0/29 1/29 4.4 % 0.33 [ 0.01, 7.86 ]
Bayerdorffer 1995 2/136 1/128 3.0 % 1.88 [ 0.17, 20.51 ]
Bayerdorffer 1996 2/65 0/65 1.5 % 5.00 [ 0.24, 102.16 ]
Carpintero 1997 1/78 0/44 1.9 % 1.71 [ 0.07, 41.08 ]
Chen 1995 1/49 0/29 1.8 % 1.80 [ 0.08, 42.79 ]
Graham 1998 1/77 2/109 4.9 % 0.71 [ 0.07, 7.67 ]
Harford 1996 6/127 0/69 1.9 % 7.11 [ 0.41, 124.35 ]
Logan 1995 3/70 3/78 8.4 % 1.11 [ 0.23, 5.34 ]
Pinero 1995 1/30 0/30 1.5 % 3.00 [ 0.13, 70.83 ]
Pounder 1997 3/61 3/30 11.9 % 0.49 [ 0.11, 2.29 ]
Sobhani 1995 0/59 1/60 4.4 % 0.34 [ 0.01, 8.15 ]
Tulassay 2008 7/315 3/164 11.6 % 1.21 [ 0.32, 4.64 ]
Van Zanten 1999 11/98 4/48 15.8 % 1.35 [ 0.45, 4.01 ]
Total (95% CI) 1335 957 100.0 % 1.11 [ 0.70, 1.75 ]
Total events: 46 (Treatment), 25 (Control)
Heterogeneity: Chi2 = 7.27, df = 13 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
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Analysis 11.6. Comparison 11 Adverse events, Outcome 6 Epigastric pain, proportion occurred.
Review: Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people
Comparison: 11 Adverse events
Outcome: 6 Epigastric pain, proportion occurred
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bayerdorffer 1995 0/136 1/128 17.6 % 0.31 [ 0.01, 7.64 ]
Bayerdorffer 1996 3/65 0/65 5.7 % 7.00 [ 0.37, 132.87 ]
Bianchi Porro 1996 3/91 1/92 11.3 % 3.03 [ 0.32, 28.62 ]
Carpintero 1997 3/78 0/44 7.3 % 3.99 [ 0.21, 75.46 ]
Chen 1995 18/49 0/29 7.1 % 22.20 [ 1.39, 355.10 ]
Logan 1995 2/70 1/78 10.8 % 2.23 [ 0.21, 24.05 ]
Pounder 1997 3/61 0/30 7.6 % 3.50 [ 0.19, 65.66 ]
Sobhani 1995 1/59 0/60 5.6 % 3.05 [ 0.13, 73.39 ]
Sung 1995 1/51 0/45 6.0 % 2.65 [ 0.11, 63.56 ]
Van Zanten 1999 4/98 1/48 15.3 % 1.96 [ 0.23, 17.06 ]
Wong 1999 2/57 0/57 5.7 % 5.00 [ 0.25, 101.89 ]
Total (95% CI) 815 676 100.0 % 4.09 [ 1.90, 8.82 ]
Total events: 40 (Treatment), 4 (Control)
Heterogeneity: Chi2 = 4.94, df = 10 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 3.59 (P = 0.00033)
Test for subgroup differences: Not applicable
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Analysis 11.7. Comparison 11 Adverse events, Outcome 7 Altered taste, proportion occurred.
Review: Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people
Comparison: 11 Adverse events
Outcome: 7 Altered taste, proportion occurred
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arkkila 2005 5/85 0/30 7.7 % 3.97 [ 0.23, 69.64 ]
Asaka 2001 15/430 0/106 8.4 % 7.70 [ 0.46, 127.60 ]
Bayerdorffer 1996 1/65 0/65 5.2 % 3.00 [ 0.12, 72.31 ]
Carpintero 1997 1/78 0/44 6.7 % 1.71 [ 0.07, 41.08 ]
Fukuda 1995b 1/37 0/49 4.5 % 3.95 [ 0.17, 94.23 ]
Logan 1995 16/70 1/78 9.9 % 17.83 [ 2.43, 130.99 ]
Malfertheiner 1999 7/97 1/48 14.0 % 3.46 [ 0.44, 27.36 ]
Mantzaris 1993 2/17 0/16 5.4 % 4.72 [ 0.24, 91.41 ]
O’Morain 1996 18/102 0/106 5.1 % 38.44 [ 2.35, 629.53 ]
Pinero 1995 1/30 0/30 5.2 % 3.00 [ 0.13, 70.83 ]
Pounder 1997 2/61 0/30 7.0 % 2.50 [ 0.12, 50.50 ]
Tulassay 2008 22/315 0/164 6.9 % 23.50 [ 1.43, 384.90 ]
Van Zanten 1999 15/98 1/48 14.0 % 7.35 [ 1.00, 53.99 ]
Total (95% CI) 1485 814 100.0 % 8.85 [ 4.38, 17.90 ]
Total events: 106 (Treatment), 3 (Control)
Heterogeneity: Chi2 = 6.16, df = 12 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 6.07 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 11.8. Comparison 11 Adverse events, Outcome 8 Stomatitis, proportion occurred versus not
occurred.
Review: Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people
Comparison: 11 Adverse events
Outcome: 8 Stomatitis, proportion occurred versus not occurred
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arkkila 2005 1/85 0/30 14.7 % 1.08 [ 0.05, 25.85 ]
Bayerdorffer 1996 1/65 0/65 10.0 % 3.00 [ 0.12, 72.31 ]
Bianchi Porro 1996 2/91 0/92 9.9 % 5.05 [ 0.25, 103.85 ]
Carpintero 1997 1/78 0/44 12.7 % 1.71 [ 0.07, 41.08 ]
Lazzaroni 1997 1/29 1/30 19.6 % 1.03 [ 0.07, 15.77 ]
Shirotani 1996 2/25 0/25 10.0 % 5.00 [ 0.25, 99.16 ]
Sobhani 1995 1/59 0/60 9.9 % 3.05 [ 0.13, 73.39 ]
Suarez 1999 3/40 0/20 13.2 % 3.59 [ 0.19, 66.22 ]
Total (95% CI) 472 366 100.0 % 2.65 [ 0.94, 7.48 ]
Total events: 12 (Treatment), 1 (Control)
Heterogeneity: Chi2 = 1.24, df = 7 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.85 (P = 0.065)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
Via Wiley
#1 MeSH descriptor: [Peptic Ulcer] explode all trees
#2 MeSH descriptor: [Peptic Ulcer Hemorrhage] explode all trees
#3 MeSH descriptor: [Peptic Ulcer Perforation] explode all trees
#4 MeSH descriptor: [Duodenal Ulcer] explode all trees
#5 MeSH descriptor: [Stomach Ulcer] explode all trees
#6 (pep* near/5 ulcer*)
#7 (stomach near/5 ulcer*)
#8 (duoden* near/5 ulcer*)
#9 (gastr* near/5 ulcer*)
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#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 MeSH descriptor: [Dyspepsia] explode all trees
#12 MeSH descriptor: [Eructation] explode all trees
#13 MeSH descriptor: [Flatulence] explode all trees
#14 MeSH descriptor: [Heartburn] explode all trees
#15 MeSH descriptor: [Gastroparesis] explode all trees
#16 MeSH descriptor: [Gastric Emptying] explode all trees
#17 MeSH descriptor: [Gastritis] explode all trees
#18 dyspep*
#19 (acid near/5 reflux)
#20 belch*
#21 bloat*
#22 burp*
#23 (early near/5 satiety)
#24 eructation
#25 flatu*
#26 heartburn
#27 indigestion
#28 pyro*
#29 hiatus hernia
#30 (stomach near/5 paresis)
#31 gastritis
#32 (gastric near/5 acid near/5 secretion)
#33 (stomach near/5 acid near/5 secretion)
#34 (gastric near/5 erosion*)
#35 (gastric near/5 emptying near/5 disorder*)
#36 (stomach near/5 emptying near/5 disorder*)
#37 gastroparesis
#38 (bleed* near/5 ulcer*)
#39 (rebleed* near/5 ulcer*)
#40 (recurrent near/5 bleed* near/5 ulcer*)
#41 (acute near/5 bleed* near/5 ulcer*)
#42 (gastrointestinal near/5 bleed*)
#43 (gastrointestinal near/5 rebleed*)
#44 (gastrointestinal near/5 hemorrhag*)
#45 (gastrointestinal near/5 haemorrhag*)
#46 (ulcer near/5 hemorrhag*)
#47 (ulcer near/5 haemorrhag*)
#48 (mucos* near/5 injur*)
#49 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28
or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or
#47 or #48
#50 MeSH descriptor: [Anti-Ulcer Agents] explode all trees
#51 MeSH descriptor: [Omeprazole] explode all trees
#52 omeprazole
#53 lansoprazole
#54 pantoprazole
#55 rabeprazole
#56 esomeprazole
#57 MeSH descriptor: [Histamine H2 Antagonists] explode all trees
#58 MeSH descriptor: [Cimetidine] explode all trees
#59 cimetidine
#60 MeSH descriptor: [Ranitidine] explode all trees
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#61 ranitidine
#62 MeSH descriptor: [Famotidine] explode all trees
#63 famotidine
#64 MeSH descriptor: [Nizatidine] explode all trees
#65 nizatidine
#66 (histamine near/3 H2 near/3 antagonist*)
#67 (antiulcer near/5 agent*)
#68 (H2 near/5 receptor near/5 antagonist*)
#69 (proton near/3 pump near/3 inhibitor*)
#70 MeSH descriptor: [Bismuth] explode all trees
#71 MeSH descriptor: [Antacids] explode all trees
#72 MeSH descriptor: [Alginates] explode all trees
#73 MeSH descriptor: [Aluminum Hydroxide] explode all trees
#74 MeSH descriptor: [Magnesium Hydroxide] explode all trees
#75 MeSH descriptor: [Magnesium Oxide] explode all trees
#76 MeSH descriptor: [Calcium Carbonate] explode all trees
#77 (magnesium near/5 carbonate)
#78 MeSH descriptor: [Magnesium Hydroxide] explode all trees
#79 MeSH descriptor: [Magnesium Oxide] explode all trees
#80 MeSH descriptor: [Magnesium Silicates] explode all trees
#81 MeSH descriptor: [Carbenoxolone] explode all trees
#82 MeSH descriptor: [Misoprostol] explode all trees
#83 MeSH descriptor: [Sucralfate] explode all trees
#84 MeSH descriptor: [Muscarinic Antagonists] explode all trees
#85 MeSH descriptor: [Dicyclomine] explode all trees
#86 MeSH descriptor: [Pirenzepine] explode all trees
#87 MeSH descriptor: [Propantheline] explode all trees
#88 algicon
#89 alginates
#90 (alumin?um near/5 hydroxide)
#91 (calcium near/5 carbonate)
#92 gaviscon
#93 hydrotalcite
#94 maalox
#95 (magnesium near/5 hydroxide)
#96 (magnesium near/5 oxide)
#97 (magnesium near/5 trisilicate)
#98 (sodium near/5 bicarbonate)
#99 (sodium near/5 carbonate)
#100 (mucosal near/5 protecting near/5 agent*)
#101 carbenoxolone
#102 misoprostol
#103 sucralfate
#104 antimuscarinic*
#105 (muscarinic near/5 receptor near/5 antagonist*)
#106 dicyclomine
#107 pirenzepine
#108 propantheline
#109 MeSH descriptor: [Macrolides] explode all trees
#110 macrolides
#111 MeSH descriptor: [Nitroimidazoles] explode all trees
#112 nitroimidazole*
#113 MeSH descriptor: [Tetracyclines] explode all trees
105Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
#114 tetracyclines
#115 MeSH descriptor: [Penicillins] explode all trees
#116 penicillin*
#117 MeSH descriptor: [Bismuth] explode all trees
#118 bismuth*
#119 de-nol
#120 MeSH descriptor: [Clarithromycin] explode all trees
#121 clarithromycin*
#122 MeSH descriptor: [Amoxicillin] explode all trees
#123 amoxycillin*
#124 amox?cillin*
#125 MeSH descriptor: [Metronidazole] explode all trees
#126 metronidazole*
#127 MeSH descriptor: [Tinidazole] explode all trees
#128 tinidazole*
#129 MeSH descriptor: [Tetracyclines] explode all trees
#130 tetracycline*
#131 MeSH descriptor: [Anti-Bacterial Agents] explode all trees
#132 #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61 or #62 or #63 or #64 or #65 or #66 or #67
or #68 or #69 or #70 or #71 or #72 or #73 or #74 or #75 or #76 or #77 or #78 or #79 or #80 or #81 or #82 or #83 or #84 or #85 or
#86 or #87 or #88 or #89 or #90 or #91 or #92 or #93 or #94 or #95 or #96 or #97 or #98 or #99 or #100 or #101 or #102 or #103
or #104 or #105 or #106 or #107 or #108 or #109 or #110 or #111 or #112 or #113 or #114 or #115 or #116 or #117 or #118 or #
119 or #120 or #121 or #122 or #123 or #124 or #125 or #126 or #127 or #128 or #129 or #130 or #131
#133 MeSH descriptor: [Helicobacter pylori] explode all trees
#134 (campylobacter near/1 pylori*)
#135 (h near/1 pylori)
#136 (pylori* near/250 eradicat*)
#137 #133 or #134 or #135 or #136
#138 #10 and #49
#139 #10 or #138
#140 #132 and #139
#141 #137 and #140
#142 #141 Publication Year from 2015 to 2016
Appendix 2. MEDLINE search strategy
Via OVIDSP
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized controlled trials.sh.
4. random allocation.sh.
5. double blind method.sh.
6. single-blind method.sh.
7. or/1-6
8. (animal not human).sh.
9. 7 not 8
10. clinical trial.pt.
11. exp clinical trial/
12. (clin$ adj25 trial$).ti,ab.
13. ((singl$ or doubl$ or trebl$ or tripl$) adj25 blind$).mp. or mask$.ti,ab. [mp=title, original title, abstract, name of substance word,
subject heading word, unique identifier]
14. placebos.sh.
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15. placebo$.ti,ab.
16. random$.ti,ab.
17. research design.sh.
18. or/10-17
19. 18 not 8
20. 19 not 9
21. comparative study.sh.
22. exp evaluation studies/
23. follow up studies.sh.
24. prospective studies.sh.
25. (control$ or prospectiv$).mp. or volunteer$.ti,ab. [mp=title, original title, abstract, name of substance word, subject heading word,
unique identifier]
26. or/21-25
27. 26 not 8
28. 27 not (9 or 20)
29. 9 or 20 or 28
30. exp peptic ulcer/
31. exp peptic ulcer hemorrhage/
32. exp peptic ulcer perforation/
33. exp duodenal ulcer/
34. exp stomach ulcer/
35. (pep$ adj5 ulcer$).tw.
36. (stomach adj5 ulcer$).tw.
37. (duoden$ adj5 ulcer$).tw.
38. (gastr$ adj5 ulcer$).tw.
39. or/30-38
40. exp dyspepsia/
41. exp eructation/
42. exp flatulence/
43. exp heartburn/
44. exp gastroparesis/
45. exp gastric emptying/
46. exp gastritis/
47. dyspep$.tw.
48. (acid adj5 reflux).tw.
49. belch$.tw.
50. bloat$.tw.
51. burp$.tw.
52. (early adj5 satiety).tw.
53. eructation.tw.
54. flatu$.tw.
55. heartburn.tw.
56. indigestion.tw.
57. pyro$.tw.
58. hiatus hernia.tw.
59. (stomach adj5 paresis).tw.
60. gastritis.tw.
61. (gastric adj5 acid adj5 secretion).tw.
62. (stomach adj5 acid adj5 secretion).tw.
63. (gastric adj5 erosion$).tw.
64. (gastric adj5 emptying adj5 disorder$).tw.
65. (stomach adj5 emptying adj5 disorder$).tw.
66. gastroparesis.tw.
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67. (bleed$ adj5 ulcer$).tw.
68. (rebleed$ adj5 ulcer$).tw.
69. (recurrent adj5 bleed$ adj5 ulcer$).tw.
70. (acute adj5 bleed$ adj5 ulcer$).tw.
71. (gastrointestinal adj5 bleed$).tw.
72. (gastrointestinal adj5 rebleed$).tw.
73. (gastrointestinal adj5 hemorrhag$).tw.
74. (gastrointestinal adj5 haemorrhag$).tw.
75. (ulcer adj5 hemorrhag$).tw.
76. (ulcer adj5 haemorrhag$).tw.
77. (mucos$ adj5 injur$).tw.
78. or/40-77
79. exp anti-ulcer agents/
80. exp omeprazole/
81. omeprazole.tw.
82. lansoprazole.tw.
83. pantoprazole.tw.
84. rabeprazole.tw.
85. esomeprazole.tw.
86. exp histamine H2 antagonists/
87. exp cimetidine/
88. cimetidine.tw.
89. exp ranitidine/
90. ranitidine.tw.
91. exp famotidine/
92. famotidine.tw.
93. exp nizatidine/
94. nizatidine.tw.
95. (histamine adj3 H2 adj3 antagonist$).tw.
96. (antiulcer adj5 agent$).tw.
97. (H2 adj5 receptor adj5 antagonist$).tw.
98. (proton adj3 pump adj3 inhibitor$).tw.
99. exp bismuth/
100. exp antacids/
101. exp alginates/
102. Aluminum hydroxide/
103. exp magnesium hydroxide/
104. exp magnesium oxide/
105. exp calcium carbonate/
106. (magnesium adj5 carbonate).tw.
107. exp magnesium hydroxide/
108. exp magnesium oxide/
109. Magnesium silicates/
110. exp carbenoxolone/
111. exp misoprostol/
112. exp sucralfate/
113. exp muscarinic antagonists/
114. exp dicyclomine/
115. exp pirenzepine/
116. exp propantheline/
117. algicon.tw.
118. alginates.tw.
119. (alumin?um adj5 hydroxide).tw.
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120. (calcium adj5 carbonate).tw.
121. gaviscon.tw.
122. hydrotalcite.tw.
123. maalox.tw.
124. (magnesium adj5 hydroxide).tw.
125. (magnesium adj5 oxide).tw.
126. (magnesium adj5 trisilicate).tw.
127. (sodium adj5 bicarbonate).tw.
128. (sodium adj5 carbonate).tw.
129. (mucosal adj5 protecting adj5 agent$).tw.
130. carbenoxolone.tw.
131. misoprostol.tw.
132. sucralfate.tw.
133. antimuscarinic$.tw.
134. (muscarinic adj5 receptor adj5 antagonist$).tw.
135. dicyclomine.tw.
136. pirenzepine.tw.
137. propantheline.tw.
138. exp macrolides/
139. macrolides.tw.
140. exp nitroimidazoles/
141. nitroimidazole$.tw.
142. exp tetracyclines/
143. tetracyclines.tw.
144. exp penicillins/
145. penicillin$.tw.
146. exp bismuth/
147. bismuth$.tw.
148. de-nol.tw.
149. exp clarithromycin/
150. clarithromycin$.tw.
151. exp amoxicillin/
152. amoxycillin$.tw.
153. amox?cillin$.tw.
154. exp metronidazole/
155. metronidazole$.tw.
156. exp tinidazole/
157. tinidazole$.tw.
158. exp tetracyclines/
159. tetracycline$.tw.
160. anti-bacterial agents/[RS1]
161. or/79-160
162. exp helicobacter pylori/
163. (campylobacter adj1 pylori$).tw.
164. (h adj1 pylori).tw.
165. (pylori$ adj250 eradicat$).tw.
166. or/162-165
167. 39 and 78
168. 39 or 167
169. 161 and 168
170. 166 and 169
171. 170 and 29
172. randomized controlled trial.pt.
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173. controlled clinical trial.pt.
174. randomized.ab.
175. placebo.ab.
176. drug therapy.fs.
177. randomly.ab.
178. trial.ab.
179. groups.ab.
180. or/172-179
181. exp animals/ not humans.sh.
182. 180 not 181
183. 170 and 182
184. 183 not 171
185. limit 184 to yr=“2015 - 2016”
Appendix 3. EMBASE search strategy
Via OVIDSP
1. exp randomized controlled trial/
2. randomized controlled trial.mp.
3. randomized controlled trial$.tw.
4. exp randomization/
5. exp single blind method/
6. exp double blind method/
7. or/1-6
8. animal.hw.
9. human.hw.
10. 8 not (8 and 9)
11. 7 not 10
12. exp clinical trial/
13. clinical trial.mp.
14. (clin$ adj3 (stud$ or trial$)).ti,ab,tw.
15. (clin$ adj3 trial$).ti,ab,tw.
16. ((singl$ or doubl$ or treb$ or tripl$) adj3 (blind$ or mask$)).ti,ab,tw.
17. exp placebo/
18. placebo$.ti,ab,tw.
19. random.ti,ab,tw.
20. (crossover$ or cross-over$).ti,ab,tw.
21. or/12-20
22. 21 not 10
23. 22 not 11
24. exp comparative study/
25. exp evaluation studies/
26. exp prospective studies/
27. exp controlled study/
28. (control$ or prospective$ or volunteer$).ti,ab,tw.
29. or/24-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 23 or 31
33. exp peptic ulcer/
34. exp peptic ulcer hemorrhage/
35. exp peptic ulcer perforation/
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36. exp duodenal ulcer/
37. exp stomach ulcer/
38. (pep$ adj5 ulcer$).tw.
39. (stomach adj5 ulcer$).tw.
40. (duoden$ adj5 ulcer$).tw.
41. (gastr$ adj5 ulcer$).tw.
42. or/33-41
43. exp dyspepsia/
44. exp eructation/
45. exp flatulence/
46. exp heartburn/
47. exp gastroparesis/
48. exp gastric emptying/
49. exp gastritis/
50. dyspep$.tw.
51. (acid adj5 reflux).tw.
52. belch$.tw.
53. bloat$.tw.
54. burp$.tw.
55. (early adj5 satiety).tw.
56. eructation.tw.
57. flatu$.tw.
58. heartburn.tw.
59. indigestion.tw.
60. pyro$.tw.
61. hiatus hernia.tw.
62. (stomach adj5 paresis).tw.
63. gastritis.tw.
64. (gastric adj5 acid adj5 secretion).tw.
65. (stomach adj5 acid adj5 secretion).tw.
66. (gastric adj5 erosion$).tw.
67. (gastric adj5 emptying adj5 disorder$).tw.
68. (stomach adj5 emptying adj5 disorder$).tw.
69. gastroparesis.tw.
70. (bleed$ adj5 ulcer$).tw.
71. (rebleed$ adj5 ulcer$).tw.
72. (recurrent adj5 bleed$ adj5 ulcer$).tw.
73. (acute adj5 bleed$ adj5 ulcer$).tw.
74. (gastrointestinal adj5 bleed$).tw.
75. (gastrointestinal adj5 rebleed$).tw.
76. (gastrointestinal adj5 hemorrhag$).tw.
77. (gastrointestinal adj5 haemorrhag$).tw.
78. (ulcer adj5 hemorrhag$).tw.
79. (ulcer adj5 haemorrhag$).tw.
80. (mucos$ adj5 injur$).tw.
81. or/43-80
82. exp anti-ulcer agents/
83. exp omeprazole/
84. omeprazole.tw.
85. lansoprazole.tw.
86. pantoprazole.tw.
87. rabeprazole.tw.
88. esomeprazole.tw.
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89. exp histamine H2 antagonists/
90. exp cimetidine/
91. cimetidine.tw.
92. exp ranitidine/
93. ranitidine.tw.
94. exp famotidine/
95. famotidine.tw.
96. exp nizatidine/
97. nizatidine.tw.
98. (histamine adj3 H2 adj3 antagonist$).tw.
99. (antiulcer adj5 agent$).tw.
100. (H2 adj5 receptor adj5 antagonist$).tw.
101. (proton adj3 pump adj3 inhibitor$).tw.
102. exp bismuth/
103. exp antacids/
104. exp alginates/
105. Aluminum hydroxide/
106. exp magnesium hydroxide/
107. exp magnesium oxide/
108. exp calcium carbonate/
109. (magnesium adj5 carbonate).tw.
110. exp magnesium hydroxide/
111. exp magnesium oxide/
112. Magnesium silicates/
113. exp carbenoxolone/
114. exp misoprostol/
115. exp sucralfate/
116. exp muscarinic antagonists/
117. exp dicyclomine/
118. exp pirenzepine/
119. exp propantheline/
120. algicon.tw.
121. alginates.tw.
122. (alumin?um adj5 hydroxide).tw.
123. (calcium adj5 carbonate).tw.
124. gaviscon.tw.
125. hydrotalcite.tw.
126. maalox.tw.
127. (magnesium adj5 hydroxide).tw.
128. (magnesium adj5 oxide).tw.
129. (magnesium adj5 trisilicate).tw.
130. (sodium adj5 bicarbonate).tw.
131. (sodium adj5 carbonate).tw.
132. (mucosal adj5 protecting adj5 agent$).tw.
133. carbenoxolone.tw.
134. misoprostol.tw.
135. sucralfate.tw.
136. antimuscarinic$.tw.
137. (muscarinic adj5 receptor adj5 antagonist$).tw.
138. dicyclomine.tw.
139. pirenzepine.tw.
140. propantheline.tw.
141. exp macrolides/
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142. macrolides.tw.
143. exp nitroimidazoles/
144. nitroimidazole$.tw.
145. exp tetracyclines/
146. tetracyclines.tw.
147. exp penicillins/
148. penicillin$.tw.
149. exp bismuth/
150. bismuth$.tw.
151. de-nol.tw.
152. exp clarithromycin/
153. clarithromycin$.tw.
154. exp amoxicillin/
155. amoxycillin$.tw.
156. amox?cillin$.tw.
157. exp metronidazole/
158. metronidazole$.tw.
159. exp tinidazole/
160. tinidazole$.tw.
161. exp tetracycline/
162. tetracycline$.tw.
163. exp antibiotics, tetracycline/
164. or/82-163
165. exp helicobacter pylori/
166. (campylobacter adj1 pylori$).tw.
167. (h adj1 pylori).tw.
168. (pylori$ adj250 eradicat$).tw.
169. or/165-168
170. 42 and 81
171. 42 or 170
172. 164 and 171
173. 172 and 169
174. 173 and 32
175. Clinical trial/
176. Randomized controlled trial/
177. Randomization/
178. Single-Blind Method/
179. Double-Blind Method/
180. Cross-Over Studies/
181. Random Allocation/
182. Placebo/
183. Randomi?ed controlled trial$.tw.
184. Rct.tw.
185. Random allocation.tw.
186. Randomly allocated.tw.
187. Allocated randomly.tw.
188. (allocated adj2 random).tw.
189. Single blind$.tw.
190. Double blind$.tw.
191. ((treble or triple) adj blind$).tw.
192. Placebo$.tw.
193. Prospective study/
194. or/175-193
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195. Case study/
196. Case report.tw.
197. Abstract report/ or letter/
198. or/195-197
199. 194 not 198
200. 173 and 199
201. 200 not 174
202. 174 or 200
203. limit 202 to yr=“2015 - 2016”
WH A T ’ S N E W
Last assessed as up-to-date: 18 March 2016.
Date Event Description
21 March 2016 New citation required and conclusions have changed No new studies identified for inclusion. Results remain
unchanged. Conclusions have changed
18 March 2016 New search has been performed The searcheswere re-run.Two references (one trial:Dum-
bleton 2015) were identified and excluded. The search
results and reference flow were revised
31 January 2015 New search has been performed Review updated to incorporate results of updated litera-
ture search
H I S T O R Y
Protocol first published: Issue 4, 2002
Review first published: Issue 4, 2003
Date Event Description
9 October 2008 Amended Converted to new review format.
1 February 2006 New citation required and conclusions have changed Substantive amendment
6 October 2003 New search has been performed Minor update.
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Medical Subject Headings (MeSH)
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